var title_f20_14_20704="Arthritis in RRV infection";
var content_f20_14_20704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee arthritis in Ross River virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling and pain in large joints such as the knees may accompany or follow a rash or occur in its absence in patients with Ross River virus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Richards, MB, BS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20704=[""].join("\n");
var outline_f20_14_20704=null;
var title_f20_14_20705="Patient information: Sarcoidosis (The Basics)";
var content_f20_14_20705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/35/5683\">",
"         Patient information: Sarcoidosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sarcoidosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sarcoidosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H481783473\">",
"      <span class=\"h1\">",
"       What is sarcoidosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sarcoidosis is a disorder that causes clusters of abnormal tissue to form in the body. These clusters are called &ldquo;granulomas.&rdquo; If many granulomas form in an organ, they can keep the organ from working normally. For example, granulomas can form in the lungs and cause breathing problems.",
"     </p>",
"     <p>",
"      Sarcoidosis can affect many different organs. Often it affects the lungs, but it can also affect the skin, eyes, nose, and lots of other body parts.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481783480\">",
"      <span class=\"h1\">",
"       What are the symptoms of sarcoidosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sarcoidosis causes different symptoms depending on which body part it affects. Often the symptoms are mild and go away on their own.",
"     </p>",
"     <p>",
"      When it affects the lungs, sarcoidosis can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Tiredness or weakness",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When it affects the skin, sarcoidosis can cause a mild rash or painful bumps. Sometimes the rash and bumps go away completely. Other times, they leave a scar.",
"     </p>",
"     <p>",
"      Sometimes, sarcoidosis causes no symptoms even though it is damaging certain organs. For this reason, people with sarcoidosis may need to have tests to check for organ damage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481783487\">",
"      <span class=\"h1\">",
"       How do I know if I have sarcoidosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no single &ldquo;test&rdquo; that can tell if you have sarcoidosis. To diagnose it, doctors and nurses look at:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your symptoms and your physical exam",
"       </li>",
"       <li>",
"        X-rays (or special X-rays called CT scans)",
"       </li>",
"       <li>",
"        Lab work on tissue taken from your body (called a biopsy)",
"       </li>",
"       <li>",
"        Tests that can rule out other causes of your condition",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481783494\">",
"      <span class=\"h1\">",
"       How is sarcoidosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors and nurses do not know what causes sarcoidosis, so they do not have a treatment to cure it. Luckily, they do have ways to treat its symptoms. Even so, if your symptoms are mild, you may not need treatment.",
"     </p>",
"     <p>",
"      Medicines called steroids can relieve the symptoms of sarcoidosis and prevent some of the damage it can cause. People with severe symptoms can take medicines called steroids. These steroid medicines are not the kind that athletes take to build up muscle. These steroids reduce swelling and shrink the granulomas caused by sarcoidosis. Sometimes, people can use skin creams, eye drops, and inhalers that have steroids in them.",
"     </p>",
"     <p>",
"      Even though steroid pills can help with the problems caused by sarcoidosis, they can also cause problems of their own. For instance, steroids can cause weight gain and mood swings, and make diabetes worse. For this reason, doctors and nurses try to take people off steroids as soon as possible.",
"     </p>",
"     <p>",
"      Medicines besides steroids can also help with sarcoidosis. Doctors and nurses usually use these medicines only in people who cannot take steroids or who do not get better with steroids.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481783501\">",
"      <span class=\"h1\">",
"       How will sarcoidosis affect my life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sarcoidosis usually goes away on its own or does not get worse. Sometimes it does get worse and can spread to many organs. Even so, people do not usually die from sarcoidosis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H481783508\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=see_link\">",
"       Patient information: Sarcoidosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/14/20705?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15477 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20705=[""].join("\n");
var outline_f20_14_20705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481783473\">",
"      What is sarcoidosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481783480\">",
"      What are the symptoms of sarcoidosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481783487\">",
"      How do I know if I have sarcoidosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481783494\">",
"      How is sarcoidosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481783501\">",
"      How will sarcoidosis affect my life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481783508\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_14_20706="Shoulder internal rotation exercise with resistance";
var content_f20_14_20706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86073/Sh_inter_rotat_resist_video.mp4?title=Shoulder+internal+rotation+exercise+with+resistance\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Shoulder internal rotation exercise with resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3eztHhn3sBjBq/RRTbuZ06apq0QooopGglFFFMyYhFIVp1FJpMXIhu0Uu2lpalwiUoIawwOK8k+MAxqtpnp5R/nXrjcivJfjF/wAhOy/64nP51z1o21JkveR5oVPWo261Kx4qM89a4Wy0Mx6/rTWWpCOwqNvTFSMsWAy3Su60UZjXI6iuG07/AFgyRjNd9oynCY9Kl7kSdkbCJkcCn+Tx0qzBH8o4qwYSQBjmuuEXY52zNEXtSXLwWluZrlwkY7nqfYetR63rFrpC7HxLdEfLCD0929BXBajqVxqMvmXMm4/wqOFUe1aWsKzZe1rW5L5jHAGjtv7ueW9z/hWMSc9eKQEDvgUhOTSsWlYM80dqPakNNIYuc03IBpOlI3TJ/SgYMee9G7FHY0ntSEKSO9NJNBwaMH8KNwsB6/4UnfilOe1JjHUcUWGG7tijPNNPrS449KYxWPTjn1pv07UrHmkB4PXNIBevakwaAetB6U2gClJyAP1qMyAcHFNaTk4oAk3Ljk4NQtN1GDTSSabxnBFFxAWz2oHSk5HtQPegYE45oODQx4pM5ANAxaQ5NL2FA60WuIPw5pRQR+lJjNFgQvfOaT6dKXGBzTS6gcDmpuUkLik3AdeRTC+aaOenX61DkPlJDIAOBUbNn6UHoelABA7VPMCQlIQeKcT+RpFpblBSY9TTsc5xRjNFgG9aKUjOKKloep9cUUUV65QUUUhoRMnYKKKKZCYUtFApFoKKKKChK8n+Mf8AyErP/rl/WvWTXk/xjx/aNp/1y/rWdX4TKVjzI8cGmH61I/JpjDnpXl2KQxutM6NTzTT1zSsFy1pozNyM85r0PRQPKQ+1cDpKky13mnzRWtusk8gVAPx/CpjrIiex1VqiiLcSAoGSSelcv4i8VLGHt9KIJ6NPjp/u/wCNZWt67cX6mCLMNr/dB5b6/wCFYQTvXatEYJdyvKzyOzsxZmOSxOSaaBxVgoOmKZsxQ9SyEr+lIRyMGp9v0puzmhARfWjBHapyAegppTk460wIaKl2Ypu2gBgBzTTnGakI9qTHY0XAiHNIcetS7fyppTP0oBjeM+9JinFSCaMDv1pNFDT156UmcDFO2+tNk2RjMjKg9zSegBjJpcc9sVTkvkVvkG4nvmoGuy5BJOPammOxfZ1AwDzmoXlJOBxVQS4HUfjSLNgYqkKxZLUoaqompfOAPPFK4WLBNBOarGcdxx705ZgSaSGTHpmm57ZqMye9J5uMfMB2p3sKxPkDrSAgnrVeSZSRjJx1NAlI+7WfOirFrHNICo6nFVy5PB5FJgk8nNLnHyk5lxnHNMMhYYpmKcOtJyHYQZxzR068U7tilIxSbCwAUnenYo7c9egpXGIOuO1AHWl4wOlKBSAYw5NHQjk/lTjnnIpcd80CAA4IxkUypMfL74pgyOaLjGkYWinEZFFILn1abyIEgsKPtkP98VyMt0c1We7b1Ir0XVscKrVH1O2+2Rf3xR9qj7MK4Y3z8ZPFN/tBsfeqfbsblN9Tu/tMf94UouE/vCuGGot/exUkepnPLVm68h3mdyj7ulSdKydClMq5JzxWuaujVc73Oule2olFFFdJoJ3ryX4put/qsS2rq/kptc5756V1ni7xILdXs7F/3vR5B29h7151K245OSetc9aorcpzTlrocy1hc9fLJ+hFQyWk69Yn/KumIpPpXJyoFM5V4JVHMbflUDqQehrZ1XxFpGmsRdX0W4cbE+dgfwrFX4h+HC+xp50yerQnFHsbl8xs6VERGHI61pTbpCNzE4HAqtpuoWWp24n066huYu5jbOD7jqKsk4AzzTjT5SZO5DtwfemlRxipjTSMVVyLERUE8jgUwxj0xU5FJge9A7EOw9sUjLgH071KetMZcnjtTAiIPfrRtyaeRilGPTmgSIWWmkc1KwyaawIxTuMix7Gk21Jg0mOM4oEM28UhFP25BPYVQudVtbfKgmVx2Tp+dNDtcuEHPT8qrXd1b2ozPIqn+6OT+VYV5q11OCEYRRkdE6n8azSvVmOSe55pOXYtQNe71xipFrHsHTe4yfyrKkmlncvK7O3qaTYCOadtGMVjJtmiikM5PANBLgg7m/On4FNI56cU72ABLIOjfnTvPkxywpmBuo4B5H40uYCQXTr97DUv2skDKjPtUJAOMfnSEUczCxY+19Mp+tH2wLghDj61UYdxk/hRt4AzSU2Oxe+0s33TwaVcsckk/WoIgcVajXjmpbb3CyHIMGpl5J9qRQPT8PWpAKEAu3NKoOR+tKMdzQwGOKGAuOaAOtCjnGDmnbQB1oAQc/40vueaUKce1KAe9Abjf50DoT3p3bOKULg8/lQIavNL0PvTu2BTW4xmgBf60EYqJpkBwzD6VBNfxLjbzTswLX06UoHFVrK6F3F5ijC5x1zVlR6ipaHsHaigdKKEB7I9wPU81A06nI3AYqs7YqFj7VpKozjUCy8oHRgaYJfcYqo7fXNRnJ6modQ0UexdeUgdR+NJDOXlVdxxmqLYqWw5mWs5TfQpRPTvC3MX4VunrWL4XXbb9ulbRrrwr0ZvFWQlcl4s8Q+QrWli/wC8PDyDt7Ck8T+Iwita2L8nh5B29hXDytuPOc9ea3qVbaIxnU6IgmYsxJOc81Cwz0qU9MnrTSDmuW9zEhAyOoAHc1574r1y7v5ZLPS5Ghs1JWSReDIfY+ld7qcbPZyRqSC/yk+3euG1G3SGMpGuBnFaLa5rTSZwN9pMkg4cMw5zVQaTK3BiH1B611LoFcg04Rjb2quc6VFHM6XbanpN+tzp0ht2Xqc8MPQjuK9h8N6uNWs8yokV1GAJY1OVz2I9jXDGIHg44q/4enay1e3YfcdvLceoP/16bu0ROCsd+fYZppGal5BpCOKzsc5FjikxUmB1pCBigEyLHNNIwakxikxQBEee1JipcfSjbQBEBz0oIzimXFxFbLmWRV9u9ZF1re4MLSLn+8/+FDY0mazhUBLMFUdycCsq81eGMFbcea3TPRayZ5p5zuldmPvUOzrg0lJl8o+7vp7nh3IT+6DgVUwO1SFfwxQVwAKTbGlYiAyMEYpCoqYrRsPtRzaFEW3IoK8dKk2kelIR3xmlIBm3pSEc9KlKkU0Lxk0gImHX1pMflUhU/hTSD07VLGhhx69eaaynPoKfjNBFMLERX8qQjnpUmOc4pMEsMUvhGWIhxxVyJRgVBAmf8atxpigBQOMU4DNKFpwXIpCYbeRxTgOvAFJjPU0F1XGWAoAcF60YHHeoHu4lyM7j7VBJfDoi/iadhF7nHJpskiRrl2C/Ws1rqU/x4z2Aqu5LcsST61fIK5pfbYRn58/SonvsHCLnPrVDGcY/Wgjn2pOKC5Ya9lYkjC9uKgeeQ53MTTSv/wBaoz1xzRaw1qOLN68+tRMcDOc98U5uBimuDtP0poLF7w5zZDHGWNbPQVieFwfsCEetbY5zWcgDHH9aKF6fjRUgeouKhK9ah/tXTycC4X8xThqFkelxGT9acoy7GVgdfl700oMcdaf9qtSP9cg/Gke7tdpJuEwO+azlGXYZHtqXTFzc89M0+NVmCPGQyHkEdxUmnKPtYHvioGekeHDstyzEAAcmsbxN4iMm62sW/d9HkHf2FY+rarJbw/ZWL28XckH5/wAfSsNr21YZWdCPWuiE+VWRLk3oh7EnJzzUZHGTS+fAekqfgaPMjPSRfzqk7mdiMgHpTSOvAp7FRnLr+dMJUnG9fzouNIrX3yxM2M4Brj7iDzXGMYPUnsK1Na8RwQ3EtnHC06AbXkVwCD7A9azNVlH2CFoOdy8+x9K06G9OLRxmoC4NzIIFXYp4LHk020upshLiAA+oOadcWrSSSF2YhvfGD6ioreAwkfMWPTJNaLY1RoTuEiLomW6AE1nQy3sk6yCJNqsDjPvV6T549veq0diY5DJuYHIIwe3pVLYGj1pTvVW9QD+lKVBPFVtHuBdaZby7cfIFOfUcVbxjuOaye5yS3I9vWkKipOmfSmkgGkIjKEH3qMr1NSmRe9RvIB6c0wGkVBcxNMhQTPED3TqalMntimmT8qLAZR0KMtuNw5zySQDSHQ15/f8AHb5a1C3JNIzE9OKRakzJbRj/AAzL/wB81C+jS/wyRn862yTjvmmEnFOw+dmIdHn6gxk/WmNpFznomR/t1uc0hyep4pWBTOfbSbof8s1PsGFNbT7lR/qW9/augJbu1MZz607IfMznWsrjP+qcD6Uz7JKpy0bg+uK6XcTweB0FIVPrmk4oOY5oQyZPyNj3FNePB6NnvxXTH8M0bRjpU2RSkcuUOM44+lM24+nr0rqtqkfdBprRgnlB+Ip8qE5nJkA//rpCuK6r7L5h4hXH+7Uc9oiIXkiQKOpxSSHzXOXxkUgX5hXR/ZYGAPkIfwpDZW458pc9qiTSKKNum1AW49yKkZ1UfMyipXh8zglgOmAcCojpsB5w3/fVCjcXMRG+iXpkn6YqJ71jkIoB96t/2bEe7/nSDS0zw7imoE8yM15pZGy7kfTioyDnrn61rf2Uv/PV/wAhTTpZydsoI9xVcocxmgA9KNvpWh/Zkn8LoT6Uv9lzeq/nTSC5nYoI4zV/+zbjPRfzpf7NueyAj2NO4XM8DJpSM54q62n3K8mJj9KZ9juP+eL/AJUasLlIgZHpTSvNXfskwGWicf8AAaYbdwBlGB9MGoaYJlMrz9abImI3/wB01beBlAJU/lUUsRZJOCPlOKpJjuS+Ff8AkHL6c1s4ORisXwmd2mp71t4468isam4xFBGc0U7vRUAZL3GOnBqpcXm1cA/N2FU5JztLE+9UHmZnyefSvUlHQmKNCO4cnO8hs+taFtLI7gF2/wC+jisWJzxz/wDXrW0tNz56AHvXPNM0sj2Xw8n/ABJbL08sVZsh/p+AP4/61xVhr93b28UEDoUQYHyDp9a63QJnnuI2bGSQa4pxsyGtTvbmBJoykqhl9GGa5nVfDFrNl7dfLbrgdK6xxxz3qB168Vm2ZXseZXmhXFsrEKWX6c1kzQyRNggj616zNGHUgjI96xL7R4pgSigH3oTKTR540bAZBP501Qw6E/nXSXujNGTtBB9Kx5rGWM5C8VXMy1Y4bXLc2+oMFJ2ynzAfr1rStZBNprDuB1rX1CwS5jCy5Rh0YDkf/WqkdMawtlXzfMEgJ6YxXVCaaNlJNGFLGN+arXa7VDqDj2rQnUAkY5rPu5Sihdrtnoqitou4yNZG2IfJySQOvQetXWjXHB4NZYlmDgtbsE6fezWpC2+MYzuPABFV5AzodBmuU04JAYyiueGrQNxfdSsBx/tGoLOBbOyVC2VQZJP61ItxA2Csi/icVm2cktxWu7wHLQxEHjhzURvbgdbYn/dkFS+bCSR5yZ/3hS5jPO9MezCkLcgN45yGtbjn0wf60hvDxut7n/vgf41YwOxUj600o2OhP4U0FiE36cjy7gHpzGaab+ID5iyn/aQg/wAqlKnPQ/iKMED5eKdwIRqVuRnz1H1Bp6XsLYxPGf8AgQpWPGOoqNo1xjb+YpDJhPFj/XRf99il8xWxtYN9DVM2sBOTGh99opn2O2JyIo8/7tAWLxfHrz7UjSAYzVA2cQ58tcd8HFH2dMYAcY54dv8AGlcaiXDKuaYZBnisW9Z4J1SN2VdvTOaas0qj72anmRSibYlHtxUgO4dc1zkl/cRD5dufcV0cS5RSR8xAz6U3JWE42HYJJqVYieuKdGoPIpzyxQkmWRU9NzDmkK4qQgdcYqVYlHGM1At7EwzEk0o7GOMkfmeKXzblv9VbKv8AtSygfoMmlcTRZUY9qpaxn+z5O3Ip3k3cmfMukiB7RRZ/9CzUeoxeVpzLvd/mB3OcnrQxpFCPO0delObpg/nSgHaCKGA9TXO73NCKNfl6c5pygYOajzMMhI42Ge70gknJ+a3TPqJeP5V1R0RkywF+tOVariWccfZ8DufMBzThNMTxbk4/2xVaEljFAU1D50pHzW0mPZgakExJGYZR27UAO8vj+tAQ445NKbtEJBiYEduKcLyPrhvyqfmPUFjbAOKl8o44/lTftsWPutx6CpFu4SMHd/3zSckmLUVYm6YpwhbnOBQtzD/fP/fNSpNCQP3g/GjnDUZ5PHP0pDEatbocZ8xcfWpI/Jbq6AdOtJzDUomEHIIHSq11CBZXHGMRt1Hsa3RbAoJF/wBX0B7H6VU1KBRp12e3kv8A+gmqUwVzz/wgP+JSmc+tbnPTFYfg7jSU/St0H86xqPU3Q2inAA80VncDz+eUgYPcdaqq+7oTz0onfcOT1FMtgXYDOR6eleu9QNC0Rmdc/WthSEACNj1wKoQFYk5xux3qVpVwORUOKKZ0uiEuOpPPevSfC4/fRfUV5l4ZbfFu/wBvmvUPCoJlj92FcNZaks9KZeM1E61ZIyKhkHXrXIznbKki9fSq7pirrrmoXX8aQ0Z8sSt94Csu504OWIHWtyROpqu6555xTTsO5yF5pjL1X8cVyHiZ2tZ1TqAOlerTRhuDXk/xEKprTIPuhRnmt6V2a09zBnkVskY5qg4Jb0pC+OccD3qCSSXdxg10xNrkyg5Oelaegwi41GOPOAMv+XasRZJ88DGPWt7wz8uswcjLKy4/CrJlsdLcj/R5+/y1YhU+WueeKivF22k5PXbVmLOxfpUdDnGGNDkGND9VFRtBGc5jj/75FTTHYhYdRUIdiMkYyO1CJIjaw5/1SH8KY1pb4J8lRU+4k96aX6jmi47lZrSED/VjPbBNN+zx45yPoxq5JGUwGOaiIODzRcEVTbIBjL/g5pPJwAFeUfRqlz74o9ealsaIPJx/y2m/Mf4UzyXycTuPqoJqzjI6g0jRsuCRwe/rVJgVvKlx/wAfHT1jXmnwq20FyGJ74xmpAM96Ih8i9f8AJpSQ0zJ1ZR9rTA/g5quAcdKs6rxeLn+7/WoMcVDWpoindjK8jpzXUuG2RbG2HAGQM9q5q66H8q6fr5WPQUrBLYRbQNgyyzS+zPgfkMVahtoojmOFFPrjn86I84JOakyeMU7mQ/k5ycn3pwOPeheRS5A61N2CCqmqc2UnpkVcUZ5zVTVBixf6iqQ1uZ6gFV+lB6HFOUfKKCorHqaFYuq5HOQeyk04zIAMbse6H/CpYxweOM1JjPB5FdETFvXUr+enqf8Avk/4UvnxjqwH1qwBj/Cnjkd+KoLlU3EC4JkUVIrq6Ax4IPQ1OQT05+tV7MDyUPUbiP1qbAQSj94ccU3B9KnnXEp700DpWMnqWthoXPGKeicGpUiJ+6M1etbB3I3DFSFyiExjA61bgs5ZcFI810Wm6MrEHYOeua6Wy06GHb8oJpEuVjk9N8OTT4Mh2D6V1el+HbG2G5oxMx/v8j8q1o4xwBwBVpEwKTdjJzdzzT40zT2mnaQLRimZHB28cYFeSSX2omCQG5n2bCGBbgjFeu/G/wCTT9KOCR5r8fgK8fuXbyZMIcbT1PtXXSV4XN4ao0fCQH9kxkd63AOOaxvCP/IEh+lbWKxnuWIB70U7rwKKnQDypvm78dKmiYRA49ahbgZ6UwvXqtArlp7kjvzTXuyBwRVB5Rz296ge4wOuMe9Sr9Ro9K8DOZLEk/8APQ9K9e8KD97Hj1GK8e+G7h9KBXoZGr2TwmD5sWR3FcNb4mhM9JYcEionHJqw4qMrnjFcZzlZhxUMmFHtVmUhMknis+d1aTy3kVHYErHnDMBVRg5PQTaRWu7tYWVcZ3dzVKa7crlEY/8AAaHuvs/nNPHEqg4j2tkke+e9cn4i8QzxW+6F1XzCVHFdcMN1YlLUsa94lfTyQsSSlfvBTyOOteV6tqB1G4eZjlmPer88skkmdzMT1JNU7m1VyXxh/wC8O/1rf2ajojeDsU4UDDnv1qQQjPNMjjeJucEHuKsbs4NJRsbJpjDEFJOKbb3TWN7FdoiuYW3BScZ9qlcjBNQLGZW+cfIOc1SV2EmrHcC6i1DRpbmEEBlBKHqvI4NaUcP7tcjHFcTC7oflJC47d66TTfEEbsIb0KjDpIp4x7iqcOxyy8i3dx4ifI7UghU2ikjn1q7eKj2byKVKFeGByDUiw4sFJAPSsWmhXMloRnnNV7gbSuK0njzjg4qlertKeuaSQXJJxudf90VXkUkHFXbtfnXj+EVWfIGBSQytBGJI3znioip4q1bD5JNv41GRnNFh3K0mQmQR1qxcEFIweflqKUErjHFWJ1G2L/dpWuMqMAOR2/SnQYaNcH6/nSspPFQWmfObHTg/pR1KSKOqY+2KP9mqp4FWtVH+lZz/AA1VPT3qZPU0jsV7oAqCe9dS3yvEOORwPwrlro8AcdRXQ3C/8TKyOf4D/KknYUkacQzA4PrTkTBp0f8AqW+tLGPm/CgyY+MYbijZ83IH1p6cPihhzQgEIweKpauP9Af/AHhV4jjNUtX/AOPB8+ophHcz1HyijFKBlR9KcVyK57XZqxsWPLcntTFPOBU0KnyZPpSQKCM11QWhhLcQAsMd6cgKylDwRVmFMyKO5NAj3X0wPUHpVpCuMIJFVbBd1upB/iJ/WtlYCBnHXtVXTIgbNCo5LkfrSsJshktnMv3SM1PbWQLA8mtNrUtLyOwrQtbRUI3DgVzt62KvoUrawLnCKK3bPT0TG/BOKiku7aziDzOqZ6A9T9BUKa8GfEUDBegaTjP0FDTZLZ0UCKqgKAKtIlYdtqcu7DRDn2/+vWrb3sblRIGQnjkcVm4tENl9FqwtRR4IGDxUyjtUMSPNvjeN2n6SD/z1f/0GvH7xcWs2M/cP8q9j+Na507Sj1/ev/KvIr2MizlY/3G4/CvRo/wANHTDYt+Ecf2LBjpjNbeKyfCi7dFtun3c1r+lc09yxB7UU7FFTcLnkTN15FV5nIxz1NPk4BIzVO4lAwOa9S5dkJO53FR09aqvKTnIH1p8xIywAwcc1WZgM9c1SBHrPwwG7Q4zzzIwr2vwmP3kQHIyK8W+FmW0OMnPMjfzr2vwmuJo8njI4rzq694TPSWHFRTN5UZYKxPovWrAXtWVrl9FY2zSzMBGOMetc0I8zscjGT3cMCGe5O0YLBD1+tedeIfHbyXDR2SKsfQvjJNZfiHxDNfnUmWQhNwjQA9FHpXHs25sH869KEFAIx7mpeeILu5yHkYD61mtcNPCUdidrcEmoGZQGJ6AU6NSsanuea2NEgJOcikJP8ROKevqKV1yKBELIMH3pvlHsKlC96cPTk0WHdlbyjjnGKlSDHzFs+gFPIxzinLyKWwczFAwvXFQyqcZz8wNT/WkKg9RTELYahNbcK5CngqTlT+FddYa/DcWqQMojmyPvHg/SuIkTaxI79DUkT5Ct61LhcR37F+flAqrcRGQqSO/NHhu9F3b+RK2Z4+hPda05IhnJ61ly2J2INRhCyKP9kVnPHyc1qS7nYF+WAx9arSRgnmo2GZsHyxN6mo2HFXDAAeOg7VC0R4HelYpMqyr8mcVPcDCx5/u0jxnI7D1olJcKD1UY4pDuViATUVpEwO4gcjjHpVrbSwAGNMjtigq9kYmqjF3x121VYYX8Ku6qM3p/3arEc1nLcuOxRuxlVJ6ZFdTNGZLu1f8AhVSD+Vc1dDle3IrriBujP+z/AEpIcmWEP7pgOtLGeeaamQpAxzSoPenuZEy/ez1oI+alXjpSGLccknn3p7CbFz0FUdZH+gSH/aFX9oHToKpaz/x4MR0LClcaKCD5F+lKRjHvTlHA+lDDOME1itzRklrETbSZH8JOc+9LaIDH8x5zVnTx/oxz3BH61OlsmOmB6V1xWhhLcbaRjzUyQOaVIydTu8D+KrUFopI4NWrW0KXsszPuEgAxjoaaRDkhsdvlcnqKo6LEDp8RI/5bMP8Ax410SxgL0rG0Uf8AEuj6f65//QjVpEp3NWRFDLxwAKw9e11bIi3tdr3Z/vfdUeprQ16/WxtpJT1CcfWvPrcvLM0tzkux3N359PwrBx1NorQ2LJJbi5Ms8jSSsPvHtW9YfuNQ8m4RCkiboXHUkfeU+/cVz/h/U7S4YRBik4JARz976H19utdMY450TzVPyOHXnGCKb0IkxurSJHrGnSMp8vawdsE4rodJuAmllrjaZVBeQHkg9f8ACs6OVs/Kf/r1aTbNGySDKtwfX86nmT0M2a2m3bJsRsF9oaSJQTsHr7delbakFQwOQeQRWHowFoZFjLEO24szZZjjkmtS0bFy8QzsOSoI6HuB7VjON9UOJwfxpH/Et0o/9Nn/APQa8lvv+PGTkEiNufwr1740gLpWmEf892/9BryG7H+iz55Ajbt7V1UX+7OiOxf8ND/iT24/2RWtjmszw4uNHtyOm3mtUDvXPLc0bGkUU4j5elFIR4o5G7A61XlVWYsQOKmlb7x9BVf72T6ivTRZUl/1hz07VHkEippiAegzUVaIaPXfhX/yAY8c/vWr23wr/rIvqK8T+FwxoSY/56Mf1r27wtjfF9RXm4j4iWekjAGfavLvitqfltbW6n5TJz745P8ASvUMgKxPTGa8H+KFyf7Zsg2T8rMfqTU4SN5NnMtzk2lJhJB79KjJCgNx1FEXMciZzg5qMNgjcflIx+NehbqaCECSUqOmetXDnOaqWY/eSkdjgVczkimydRBVC71S3gEgQ+a6DLBT0rQ9B1rmisaahqUbFQhQHJ/GlI0ppN6lifV5Rp8U6RqjSsApY5Az3NOtJ7p/NR5oXYA4ZD0NRWKu3h9UNuJdq/dPeodKgdtR8+G0aCJY9pVlA3H6VLbRpyoda6zNFZyG6UNKp/d/7fOKuWOshrA3V3H5ZBxtXnJ/pVOwshIrfaIXjaGRpE3VUX97ot7GudyyZ6Y75zSuw5YnT2N9BeKWhfOOoIwRVpeTkVk2kcDSwTCXE2wDbnhh61s9emBWi1MZRsxkiB8Dt/Kq8SbAV7ZzzVvnPvUEvCs46VZnc0vDszQ6taFiF3Psb3BFd+8fpivMIWInhOfmQBiPevSo1ge2gkDvmYKQA3rWU0DGSRc/0qq6EEmt2/gjgkCRrhQo96zpEBBJ7Vi0Tcy5Ace1RMpGeM1Yt7RpbfzN7Ecg+3NNkt8cbzik0VcqsnQ1Eyck1YkjCLkuamvIFiEYToVzn1pWHczmX2HNJbgiJMehqcr+NLbpmJMj+GlYbZzurA/bT9BVcrir2rjF+R/siqu2sp6s1jsUbtflHqSK60j50AzwK5W7HKf7wrr2QgpxyRRFOwT2BRzipVXHU05Yj5ZIx70qoSwx1qkjIcF+Xij0zUqIORTcetIBCM1R1kf6Cc/3hWiAQetU9ZUfYjnuwp2GjNUfKPpTivT609UICj1p23n6msNjUu6bFm1Q465/nWlFABiotKiDadkkqVUtkc96tw27yKrR3YYeoWu2OxyTepIkYAAxViNBkHFRpZT4G26/8dqK1kmXUriCWTesYHOMc1VjNl8DIrC0Yf8AEsj7Zlf/ANDNb4HFYei86ZDj/nq3/oRpjiYfjqcm8ht+wwx98CsPTFclDLtLY3HFaPjb/kYG6/6sD9KxDPOjqLUPk9kXd/Q1la7Or7J0zaba3zpLLGBKhHzDgsB2PrW06uYz5RAfsSK57w3NeTSyi6WRFVRjcm3Jz9BXSDpUT3sYsghF99oTO0w5G7JGauub1WJt0BUA9cH6YrJ8Qaw+j2BmhtXup24jiXoT71Xj0e58U2um3utTiCFcTCztiQpz03MeSfw4pJK1wt3OwglS6hMX+skABYIxG1vcjoa2rC0jtI0kieYlSCRJKzjrz1PvWZYxLFtSJAiLwFQYAHsKnt764wYLmIBXz5dwgJSQf3f9lv0Pas5a6IlbmH8bgBpel+n2hv8A0GvH7ogWdwD/AM824/CvYPjdxo2kcc+c3/oFeR6goXTnYYyYW6963ofAdMfhNXw6mNJt+ONg5rR2gDPNUtAGNItgegQfyrR28/0rCe5QwLkUVJtoqbgeETjCEjvVUNtUHqMVJJJvOUIyB36VDKSiAdzzXqRVjS3UgkIIJAPNM47d6kPCkHrUWcHmtBnsnwsx/Ya/9dG/nXtXhXGYiPUV4p8KRjQo9o6yN1+te1+FR+8iU+orzMRpIzkehXTbbaUk4+U8+lfPfxJm83xECp4RABXufiS6+y6PcPn5iu0fjXgXjQhtauCe2B+grXCrRmC3MuLibPQMKqy5y6jg5yKmRuP9oVI4D11JFFKwlwoXrkk1oRuCuayoV2XUmeg+7WlDnZuJ9qTKRMpLVn3ekW9zd+fJu91BwD9a0kPHSgcjgcUmriTtsNAjt4MYAjQZrDn1eWXP2fbGu7aO2au+ISw0yXYccdqxNMsZLxooomwAFUE89ambaNqUebVmhbarMjbbkI69yK1oVgnUyIq4Yc8Vk6xpQ0wqrzBpXHChce3NHhOVms3jLFtjFcmnFvZiqR5VdF2HR7WK7W4RSjDtngfQVqjB6VF0NAY5HNapdjByctx8lVJzmMp0G786szt8mRVAy+dcsq8BeKaJLdqn3n7tXdaDP52n2I7xuUP4HiuKiHygV0fhKYfaTCe7Bh+dTJD3O61Pm5I/2RWdIOG+laWpjF1+AqhJ90/Q1i0Y9SHTE/4lchPv/OoHjBPTmremL/xKG/H+dQkUmirmVfx4RfrVy/jwYuP4Kj1BMovHO6reoqf3X+7U2HcyGWi3H7qPj+GrBjyeadHFiOIj+4KTKuctrA/4mLdcbRUG3061d1cf8TL/AICKrsB+FYS0ZstilcICYwf7w/nXZPH88fpiuTmXLp2+Zf512sifvUz6GriKb0ESP9y/rxinwx85A5qWMfumOKfEvJ+lD1MiGOP5uc0hjUORjmrSj5uDQVGeBzRYLkBjxn0+lZuuJ/oOc9HWtjb+VZ2toBYcd3FDQ09TNC8DAwMU7Z69DUm0YFOxyOtc99TQ09MGNNf3jb+dJpI22x/3jTtOXGnP/wBc2pul5+zn/fNdsdkc0tzVtx+9U1UQf8T29+gq3bf6xMnvVaMD+3L0+wqzPoX+1Yeif8guHIx+9b/0I1ugcVhaMP8AiWQ/9dW/9CNDKict4+jYaxuB2hkABHY4rJ04qhDSsoOMkk4FdV46tWkQSqOVwePpXFFRIu0jkdPpWKs2zpWsTqNN1a3lvY4IyzB1OHx8rEdh6/XpXRAZrg9FtGk/eTS+UCQ4CYL8HjJ6fjya7mKdWC+pqZJGciG4njWeHzYpfkYENsyCfar2g3EdzaOsDHEEjRMD1BBzg/gRVe8kIUFRzkGjw7a3VtqesefIGgnmWaEAAYBQZ/HIqWtBPY6ITJawyXEvEcalm9cUtha6ZcGG506GLzJm+WWMEHJ+9n3+tZ2skyaSWjWOaFSGkQk/MgPJBU5BHX8K0vBOlCyMshYPltwYd89PxxWb0VyUY/xwx/ZWkAf892/9BryXVAf7Ib2iavWfjaf+JXpQ/wCm7/8AoNeTapn+yjnvC2K3ofAdUbcpteHx/wASq2/3BWmRzVDw+P8AiT2v+4K0Oc9OKwmrsAIop3YgdKKkLnztKQityBkVXJycE/KP1p85zgH9Kh7cEfQ17HQ2sBOcjoMcUwnjml6ij1p2BHsvwp/5AMeTjLt/OvavDAHmR/UV4n8KiR4ejY9A7Z4r2nwhMtwlvPFkxyYIyK8rEP3yJ7mp8Q7zaLOzGfnbeQK8a8SEPqdyxJx5hr0Lxfdm48XsuSVjwoFebao2+7kY9S5Ofxrsoq0TAqx4DA9RTm+UnnpSooUdOtNnzs9COK3QGWsm/UsLwuK1S235R+FYli267lJ6qcVswgMd7kkCokWWIwVUbj8xqXHOM8VHD+8JYgD0qbuaIkMhurdZ4GjboaxI4ptOV4owVUjGT0YZ/Suh9MU/buByAQfUZpyVyoTcTlZhPqFyzXEksr4wMkn8jW5plgLG1CdCeTVxYlXkBQT6DFK3TmlGNh1KnNoMPSo2bHvUp+771DIcFR71ovIy2BmycfpVS1I85zjGWNSB9k5Hoe9QWJyhbuSTTt3K6GpHxWlokph1i0fOFMihvoTWVGSCAc4NTZIYEZz2qWJHruqD/SyfYVQcfK2PSpIrkXlnbXAbO+JSfrjmuS8e6nLZ28FvC7RrNkuyHDEDtmsHuRGN5WOn0sqdLcKysRkEBhkc0xhxXlGlXc9rd+fZsUcdST94eh9RXW2XiwlimoW2P9uHn9DSbNZUWtjdv/8AVoP9qr+ogZjGOiis2aaK6t4ZoH3xucq2Otal/wDfT/dFIyaM8pxxTo0Jii548sdaccCpo1+WPpjyx/KluNHIayuNWYdflFQFDnpxVzWRjWWH+yKYqZGO/pXPUdpWN47GbIgE0S994z+ddvIn+kLj+6a5CaP/AEmHj+Nf513EkYFwM8/KaqGxNQbGuIscUqLjmplj+SlRCSeOK0SMWyILz70Y5qbZg0hXmhoLkWBWfrq/6CPTzAK1CvtWfri/6Cvp5i0mhxepnbeBSlQBnnipFX5RnrSlPauTqbF/T+NOk/65t/OmaX/qTxgFjT9PH/Evk/65t/OjSgPsx/3jXfH4Uc0zRtl/eJn1qsg/4nt59BVy3/1iYHcVVT/kOXv0FUZXLo6ZrF0QE6XCT/z1b/0I1u9uKxNF/wCQXB/10b/0I0XKRLrNsJwyt0IHH4V5vq1i1ncMq5xnIr1e5XJ98CsXU9Mju0KuvPrXLz2kdEZaWPPoLxojmFVJHVc9DWxotw7XEsktwZGChcdEXv8AKP8AGqup+H54J/NhBbbnGOKqQtNbv88DqwP3lH9KvRorludcb+Nrkwg7nRN7HsPQH61LqNzMIoigXdLsiIPAIJOR+Vcxauh3KDcfOxdjsJYn6+ldhpGnXmoOjNbtHEORJOBx9FqG0tSXGxN4Itb3+zFsp0wodtjN18vtketeh2sa28SRpwqjA96oWFpHaRKkZJP8THqa0ENctSd3oZnn3xs/5Bulf9dn/wDQa8p1fnSTz/yxavV/jKAdM0sntM//AKDXletYGjnjnymOa7aP8M6YbG1oS/8AEqtQP7g/lWmuc+9UdCH/ABKbX2QVf/mK55bgJ1NFKDzyKKgD5vYgn+lQE85PWnufm4qMivaR0CE80CkNL2piPbfhIkbeHESV/LV3cF8Zx71634NRbXT7SNZBIkIADj+IA9a8h+Fo3+FgoGSzOBmvWPBNrt020s7lAfkCSL2PqK86vbmMp7nNanfhtWv73IHLbNx7561ys37wuQck89O9afxK0vTdK12e102J0i4LKzlsMfTPaubsZ/IHlzE7Ox9PauinJWsS6btcuqxHJqC/OyN2PbnrVrKsuUK465Fa3gvTBq3iSIyx+Za2im4lBHBx90fn29q3WmpBx9nay208qXCFZGO4g+h5FacY4Cgc1e8QbZdTkkIxKWbcPTniqsK/PnjNS2VcsoAEAxzTuhHvSAc8UHimtiGPI4yKFx1pFzjNKD24pkiml7+tIx6Ck6mgBSuV681Vm4I+tWjhV3Dt61l3UhZyB0FNaDQy5O25kwf4SetNtRsRFzziqU8my7ct93bT/t0MMeXfnsMZNNySRdm1obCPhuSPpVh2wN2ce9cm2qyux8mPA9XPWtHT/EN/ZsrRxWsjqQVaWLdt/DOKz5l1KVNs9S8HTSy2DQsHKIcxsVwCD2B71hfEohJYHaWFsLtEO8bwSeuPSuY1HxT4h1UMLrUGjXGNtuoiBH4c1jRxkSF3Ysx6sxyfzrJy1HCk07l+08raSznce+cVa+UPkMxx6tnFQq86oP3I24x8uDUtuhmdUVCJHIUDpyelTa50XOs8OXpa0SzlQrhyYZOqv3I9iPSu01Dh09dgrmtRtLOw0W3svNWGSP5omXl/M/vAdTzVa18WXN6yw3VglndKAjNO5RM+vI4z6U7HJON2dCasAYRPaMD9KzreC6D+bdXKvxxHEuI/z6mtJfuqP+mY/lRaxlaxyusDOssP9kVRstTtbu/uLSIv50H3twwCOnBrR1Rc62ef4RXJeHAP+Eovz22v/wChCsOVSubR2OkKg3ltnvIv867aRf8ASB/umuNyPttr6eav867dxi65/un+dFPZkVA2ny6dGnWpAPkpyDitDFsiCe1IUqYCkxmnYCEoOKzNfX/Q4wP+eq1sFegFZuuDFrF/11WhrQcdygsZAoMZqyq0bQRXF1N0FgALCUf7Dfzpulf6hs9N5qSyH+hS9/kb+dUNH1Swed7CO8t2vVYkwhxu4613R+E5pbs34P8AWKPcVXUf8Ty8HqKsQ8SLn1FV1/5Dt2AOdoNVchIu9vfFc/p0vkaCJiN3ll2x64JNdCO+eBXNQEf8ItNyOkvf/eoSuyop9SHwT4lfxNa3Ms1skDwOq/I2QwI46966ZI1blhzXnHwcI+xakQc5ePp/umvSVOMc1w11absb2sxhtkbgjINIdLt35MSk+4q2pI6VOnQZFZc3QV2tipY6fbqxPlrkHjArXiAUACoIxjOO9TJ6Um7ibZOpqZTUCHmplNRYk4X4w/8AIK04/wDTZuv+7Xk+s4Ok4/6YtXrHxgG7RtP4z/pB4H+7Xk+tnGmSA9ViYN7V6NDWB0x2R0eiAf2Raj/YFX8flVTRf+QXa+nliru32rnluDG49OtFOx+dFSI+Y2I3EijJPJNJRXsnQDHn6UdqDz1pB2oA9t+E5x4biwOrsP1r2Pw6QkkUhIAUgmvG/hQQfDsAA5Dt/OvUvtAt9JuJfRCPzrzK6vMzlueb+Mr03+vXM7Nyzk/X0rJIBXjkik1WTzLt2X1qKNiPatVobW0Hj5RwSD7V7H8N9N+yeCXu2jzc3m5yw6lc4UV43KcxHHXHFfQNsP7K8IWUYUZit0GPfbWkpNWRzVdEeU+K9Kn0/UUM+B5yCQKO31rNhXA9q6HxYZHjtJZWLTOPnOO/oPasLHYGtetzNPQWlxkcUg4NPX2poTE6Y7cUoznNBGe1HTqaoQ4deR+NA7jFKCaCOetArkcvMbAdxWM2d341tOvGaypEw5GKGylqYWryeXcY/vqKghRpTlznHT2pfFCtG1vN/wAs87SfQ0unyZXjms56nTTL8NqMZIGKsJEi9RzSRyDaATUUlwqjk89qzaNCxlVHJqldXCrHjjg9qfZW93q90LbToWmmJwQOi+5PYV6d4Z8F2ekQ/aLzbd3+M7mHyRn0Uf1pqNiJTUThdO8P+ILu0W6ttOmaF+QzMF4/E5rqNE8J6tFMk15dw2mw5AhxK/5kYB/OvQbP/kE88/8A66gYZHFNs53WZkrp1taOjRqWnZvmmkbfI3/Aj/Sma54n0qO8e1lZ5SoCviPeufT3q/c8NGO+6uV17wVOdRmmsbmIpKS+yTIIz2zSWrJi77k6anpGT/Z+pGzOMeWVJjP/AAE9PwxWkmtxQwq920LxBBma2kDqP95fvD9a4m48NaxbklbdZVHJ2ODn8KzdYtb2C0/e2rREj5S6EA+nNU10NOVPc29V8ZaJHrO6a5ZI2wFkMTbT+NcBrHiq40jUGutHeBvOLJmRNwIznIrntIucTTRagzhNxyr8qT3rrtFvrGwumnhitrkMmzbKuVXvkelHIo6miikjE/4WH4hkdW8+1UqQw2244rRX4neMGkVjeI8in7otl+bnpgDvXX2viK1aaGRtOiCq4LCEIRwe2RXaQeNtBaYFopbXA6tbDA/FaFJdETJaHWWLvLYQyzJ5Ujxqzof4SQCR+BqdBx7Vj2viXRLpcQ6paFyfutIEJ/BsVrwMsozEVkHqhDfyrNpnJKLHUcdhR7EYOelAx0ouICKy9dI+yRZH/LVa1Ky9fP8Ao0P/AF2H9aT+Fji9SIDAxjJo5pc0ZrhN0JYj/RJeeNr/AM68X8Mnd4zsCCRm9z+pr2iy/wCPWY9grfzrxXwo6p4wsCzBVN2eWOB3716VP4SYdTqNd8c6vZ65dW9osKQwSFFR4t2cdyfeue8S+LNS1uxlgnWGJpivmNASpbHbrwK9aubPQb+YPepp8sh4Lu6g/nmsG68N+FX1OeEtbwxKPlKXYXB+pNUKLS6HiNxBdtgKWIXsZCP61mSfaLeRhcblVm4G8nFe/wD/AAgOg3odrDUJSV+9skSUD64rz7xT4B1CSxhutMRruKRjkKPmQg4wR36dqCrxZP8ADHxNHoNy9rcxg2l267pd3MR6A47j1r3GCWKYDypopP8AccHP5GvlyS1mtn2XMbRyINrRsMEH0xXYeE/ANzrmlDUba9t7VZGZVTY27IOOq1hVoxlq9BySPfsFRyCPrUsbYGDXjUfgfxdYA/2fq5Ydgl26fz4qRYfiTYDKyXcqjoFaKfP581yugvssXL2PaE6VKp6+leJf8Jp4808ZurESKvXztPZf1WnW/wAY9UhO290K0Y9/LmeP/wBCBpPDS6E8jPcFqUV5FbfGawOPtWjX6epjkRx+uK2rP4t+GJsCZ7+2z3ktiV/NSal0J9hcjRd+LXOi2J9Ljv8A7pryXWzusbo9R5ZruvHvi3Qdc0m0j0vUorh0n3MgDKyjaeSCBXBam6yadclWUjYcYNddBNQszoS0Ou0TnSrX/rmKu4qnof8AyCbX12Crw96wluTcQDmiloqLjPlyipTDJgEI3PtTTG46qw/CvYubtDOtWLSAzSBTlV9cVEI3zwrflWzp4BhGPXp2oYj1P4WQtFoUaNxh26fWuz8TXBt9AIU43nHFcn8OznSk9PMatjxzMBZRxjpiuCov3hO7OGB3OSeamVeKrxn5h9atKM84rSOxqWtGtDe6vZWuOJZkU/TIz+lfQurRpJbiNvoo/DFeMfDaHzvGNlkcRq8n5D/69evahKftKjsowPc0/imkcldnl/iCdZpjGM4iwDkdCO1YuQTXQeNfKh1M28Iwcb5D6sa54cdK3e5Edh+Rk09elRoc9RUo4FCGwOTRyfanDJHFCjnnirJAAEfNRn06U7jNGBnjGKLgRvkrVK4iGTycnmtA/SgRBsk9aJK4JnOanYi7s5Y3BwRkEdQamn8Ca5YrDJY20l/YzIHhniA5BGcEZ4Nbfkpg5AweOelem6H9uvdAsfsihIY029Qckcd6hopVHHY8Zg8JeJLk7F0qaMespCD8810ekfDgi7txrlzuV2GYICR+bf4V6abDUzy0mB/wH/CiHTb0XUUkxDhT1JHA/CpE68mQrptnpC/ZdNto7aBQBtQYz9T1NNl/1b/Q1d1P/j7f2qjJ9xuO3SpZle5NaDOkqe//ANeq5+lOjtrp7GOIMsagfN83OaYdNnxzcD/vo0gK1zy8XX7wq5qXE4+gqJdMcOpacMQc4JNTahtabIORgUrDKbHKk+grM06FL2G5trtBNA4IaNuR+FajD5T9DVPSraS2eQSLjcMg57UtbopM+ffiPZw2etPBbR7Y0kdOueB0z6133wwijbwXbq8cbZlkzlQc81xPxQUf8JDc/NhjM5x6813HwuGPBsAb/nrJ/Orru0De90bMmkadcXtur2UHzyAEqNpxn1FW9U8GWFzrEllZvLZ4i8xWBLjPvnmnxf8AIQtcf89VP611jW7DxB9oyCjQlcdwc1z05MmU2jz258A3ECMZryUKP+WvkCWP8QvzD8RVZfA+riLztKnsrpByrWtwYT/Tn61678wTKcnPSqktjBNMZGia3uD/AMt4G2P+JHX8c10KTM/adzynZ4z0g5Ya0iDureen5c1JB4+16xfZevC5H8FzaGM/iwI/lXqA/tKyJKGO/iHb/VSr+P3W/SiLULK8k8i4wk5/5YXUe0n6A8H8M0+ZdgUkzhrP4lyvgXGlxSKPvNb3GP0Yf1qe+8daXdwQrJFdwFXDHcgb9VJrqL/wpoV5k3GlWwkP8ca+W35riuT8QeA9KhSN7O4vLcu4UjzPMH/j3P60PlsC5WzVtPE+i3XEWp24Y/wyExn/AMexWvDLHMFMMscinoUYMP0rzu78AXjg/ZdTt5wf4biMr+ozXGaoJdDvZba6jeC5jIBaJiuc9CpGCR71zeyi37rNVE95ss/ZZw3B2vx+NfNutwvLaXEUUbys0hIRAWY89gK6OHxPrOhSqjale2RI+VJsOp/76yKzLJ7WWczi5fud0bYIY9Tx9TXTFcugRjy3OOhtLll+W2U8dwKnh0u8uTtttPnl2/e8uBmxn6CuitYWvrySC22qgJPJxxW/oJvvDmow3tlIwZDhk3/LKvdTWjmU9diz8F9E1ax8UPcSWlzbWotnWcyxlA2fugA4zzXrWiY/su2x03n/ANCNc7F8SrVlxfaddQn+9G4kH9DRo3jDQ1tLeCW98l1Yk+YjKBye+Md6zbOdxk2eX+PJWPi7V1OMfaGx+lep/CVj/wAIXb5P/LWT+dePeN3ebxTqdzbZlt5ZWZJF+ZWHqK9c+EhI8D2ZI/5aSZ/Os8R8OhpLY7yNh3z1qyh6dq5rxEmtSW0DeHJ7VLiOTdJHcHCyLj7uccVzGs+LvEmkafL/AG14ekiiYFBeWUolRCeN2ODXJGk57MiKubHiP4iWunzy2enL59yh2GR8+Uje/dvwrO8O+M7q91aTTNe0+0uZdpddsAyyjk4znPArxr+14Jrl44vNbBzvddufwNddb6//AMVFoUirme2BBk9VKAEfp+tdkKCSszRq2x7ZL4X8O6hGHl0awYMMhhEFP6Vk3Pw18LXMhEdjLAR1MM7D9DkVr+Eb37doME/f7v4jituL5Qc9+TXDUqShLlTMuZnj/jf4faZolnBc2V1dgySeWVkIYdCfQVwup6K1vCZhKHTbkcY4r2j4rHOi2eP+fj/2U15hrwzoi/8AXBufXmuynJyjdm8XdHWaIB/ZdqMZ/dir2B6k1S0Uj+yrbH/PMVermnqxMbj86KD60VAj5wa/gHCIT6mon1BeNqfXNZueKbnPtXscqOk0X1DeCNg5FXNHbekmeueKwxwQa3NEAKE0mhM9d+HTZ0he37xv51c8cvzGvH3RVP4e4/shCD/G1WPHH+tjB7qMYrgn8ZMdzlI/vcVcHQ4qpEB3HFWGOEJPpmrgbPY9E+Dtpu1C+vmHyxIIwfc8mu1LjdNf3U6rEM7VJ4rM8E2B0vwEXdSJp42nb15HH6Yri/E97NceXFvIhRVAX3q6TTk2cVVczKms3gvdQmnXO12yM+lVh3qFB8vPapT1rZitYeuc9akAFRov6VLjgUITFA5ApWbnFNIpcc1RItHGeDxSk+tIeT1oAMg4FSREDjpTAKU8GqEPKkq3p1Fd54Hnb+xPLDsPLkbgHpnmuFVtyqfSus8ESc3cTHrh8fpUS2Ezqnkc872/OoTI5/jb86c5GKi71kZjWySSSTTSD6VJj1prDnNIBhzTT05pzGkPSgZEepph9akbrTKQ7jH+62D2qXbwp/2B/Kom+630qw2Mf8AH8hQUj5v+J+E8SXXBOZ3P0rufhfz4NtznrLJ/6FVD4jeA/EE2tS3EenyPHcSNJGwZcFT9TxW94J0u70jw9Fa6hF5M6u7bCwOATx0qq2sDo0sbEI/4mdp7SL/Ou3b/AI+h/un+dcBY31rc6zDFb3MMssUqh0RgSvPeu9Y/6aB/sH+dc9NWTuZ1EWVJp+/jFRinDrWhgxwwetQ3Wn291GY540kjPOx1DD9an4AozxxTBOxmHTZrRALC7kjQf8spf3sePbJ3D8DWNr17LBHAL+1dQJQfOhPmRnj/AL6H4iuqfpWLredtuckYl/pSk7ouG5ThuElQPBIroeQVORVHxVZ2t3oGoSXNtDLJHbOUZ0BKnHY1ZlsIJZDJtaOb/nrEdjfmOv41zHjjUtT0bSpYnNtNYToYmuJARIuQeCBx+PeuWCfNodMUeC6vClvLEIlKArnGcjNdp4R8Pyat4Evb+whMmo211hgg+eSLYMqB6g81yGo273jLJbPHMMbcKwyT9DXr/wAErK6/sC8ieZraJblWYIMSOdo4z2H0r05Nco6nuo8rtnvbG4WZELKWIfHBX1BFdNZ3d3dws8FvJIqjLYGcCveL3TrC8+a8sraY9SXiGfz61hizjluRaWtrFb2f9yNcBvr61LkmZKskeRnWHgAWSKVV7koRS/2paScSRLk9exr3dNFsbWxmjs7G3MhRtgkXcCxHGc9s15J4X8N6lqV1P/bWkj7LuZRKI1Rt2eikHpS0GqyZkCSylXMZdD0wDkVYtvNhwbDU57cjoFkZQD9M4ro5vAWnS7jb3FzbsOxO4Csi98B6hbsTaX8EueitlKhtdS+dPQsw+I/FNoA6alHcoOSJkVxj68Gm6r49n1TTZdMv44CZCuJoo2QBgcgYyax38OeI4UbNnJOv/TJg/wDKqeh+GtR1XV0t4rW4STcFkd0Kqi55Jz3qWoDSSKl9LHCjSSbTnpxWfo9xJJeyXGMN/q0HrXrfjj4dQzC4vtPlijtkjMjxOSuMDkqR646VnfB7wrbahJ/bN5l0tZNsMO35S4GQx+menrVKrFRvcT7nVfBfVTc2GqWUhIaCZXUHsCMHj6ivTFOAefrXiGnT3+g/E/WLbTrRrma8ZtsSuqZz84bLcYHPqfau3GleKtVOdR1Gz0qAnPl2ifaJfpvf5R+C1x1Kak+Zu1zKS1uT/EkLeaRbiOWJRHNveR5AiKMHksTivLNZnhm0hxbTxXEaRlPMhOUJyOhxz+HFdb458JaZp1ja3LC4vbx5trXF7MZW6HoDwv4CuU15QuiLjA/cHoMfxV1U1HksjSJ12h/8gm1/3BV7PHFUdF/5BVqP+mYq7gYrkluJ7iN/Oil6HHeis2NHyvjHFJ3FOI5oxzXtnQJ/EK3NE4jkO7v0rEx71dsLw2oIKblbnrSZJ7Z8PP8AkEJnrvb+dW/GozLH6hRWf8NZRNoUMiggM7EA9uaveNWHmoO+0VwTfvkx+I5ZBir+k2T6rq1nYqOZpAp+nf8ASqUYyuc13fwl0/z9anv2BK2se1T/ALbf/W/nVXsrmktEdjdeMvDiSzaO2oxxXEY8gRupALdAAcYNcFrvzagyc4jAB+td/q3gfw5ezNeS6ZGtyG87zY2KksOcnsea83vHaSeRh/ExJNFKSeqOXzID8uAtO/lTApTqMk04c10IGSZweOKmJwB2qADgZqZOnNWSxe/FLigdaMUyQ5NAFPA47fjTgBnIosBGvDdTUjDco200gZ4FTR9MAZ9aZJHAfm2kcGtvwzKbbWYlYnbKpT/CseUeXIDgGrtqWkuIDExD7wFI7HNJrQEehMc0zvzUKaTeMOdTk/74FMl0qSOWJZNSnLucADisbEtFk01ie2KmuEWOUomcADr1qtPxFIcnocUhA2c8imk8GoLPR4JLdZZJZssMkb8AVK2k2YOWkc/WSgY3cuDlgD7mmE5/xptxYWMewKN7s2BljVm7RYnEaAKqgAAdqkZXb7rfSp26n/cH8hUDHg/Q1O4x3/gH8hQCZpeLvu2HtHXH3bFJlKhc9eRXX+L+mnn/AKZ/4V5d8RPEB0G0haBQbmYgR7lyoGec8+lFS9tCoasoeHvDK6X4r+3/AGsymeb5EEYQICcke9eqsP8ATs/7B/nXG22W1GyJ/vqc12bf8fnXnYf51nCTluXV0HO2BUTXG2pniZhlCMjsaqyxyLnfGefbIpmNxy3wB5/KmXurLbRqwiMpY8Kp7d6oXED53Yqhf2xuLWSAu8avjcV6kelJt2NIpX1L7eIYZLgiCeOOJAu8sMlmPQD29xRq06TQ2zIchpAf0rlb7QrcR5t4lWbIw7k8e/5Vc1CZo7a2C5ARuv4VF3Z3NOWPQ3Q4ODmqPieKObwxqqSosim2c7WGRkDg1Xt7wYGGqTW7lX8PamvAJtn5/CsI3uUkfMmpKoljkQAKUx07ivZvgjAbrw1fOZ543E4UNG+ONvSvH9aXMkXQYTIHvXs3wGA/4Rm+A/5+R/6AK76zap6FSd0dnLYXIODeSSqezsVP5jNO0xTp907yW83lMMbwRJ/LnFafTPSkIA5HB9u9cca7W5k4IV9ZsVZFNyqs52gMCpz+I4rm7rxBaaJZaaL3IF1ctEGBGE5PzH2roJFWRcSKHX0YZFZWpaDpepRhLyyjdAflHQD6VrHEJ7kKmkRWkyzl3jYMmeCOhqHUGxKgyfu54q1DpP2OIR2U5jjHRHQMKUQOJvNubVbjauFEb4/Q0SnFqw1GzLOkYjAIGPcVuCQkDdk/jXEN4glsZm+0aJfJEDw0abx9eOlamneMdGuwFFy8TAciSMjH44rGVNvYeo74j3n2PwVqbg4aRBCP+BHFN+FtoLTwTYHGGnLTN+J/wFc58YtSifw1YW9vNHL9puQflYHhR/ia9A0i3Sx0mytV4WGFEx9BQ01Cw3ojz74jk6J490LW0OFcKrkf7LYP/jrV6wGDcqeCMg+1edfGKyF14Wiu1+9aTgk+itwf6V1Hg3UP7S8LaZdclmhCt/vLwf5US1gmEnoZnxNP/EmtOn/HwP8A0E15vr/OiAHj9yf/AEKvSPiXhtItQe04/ka8514A6MAf+eH/ALNW9D4Coo6vRf8AkFWv+5V4Y71naNn+zbYHslX89Kwk7sbFI5oo/WipEfLQxmlwDS96O9eydIYApQcUfSkzSEe2/CoY8NQZ/vv/ADq94yb/AEgAYyFH4VnfCck+GIv+uj/zrQ8XpuuycfwivPqL32JfEYSr+7BFex/C+yW08KW8u3ElyWmc+uTgfpXjwbbCe5xXvmgxrb6JZQx42pCgB/CitpAKr0LOoqz2VwkZIdkIBH0rySWyMYZeeDg8dK9ekmEKGVgCqDcc+leYa5cieWWWDb5MnK46ge9RhtEzlRgTuHfEYO1eM00DHXpUmV5zikzHn7w/Ou+KGOXnp0p+NwwKahXPUfXNPLKo5IzVpENigle2aeBx3/KmLJGAODj6U8PnsfyoEOU9jTiOeOlNjY7cbCfSpRvOD5f05poRH0pycY5GaMNuAIAzThCc9+ewp6ASEo+Ae9SW7fZ5FZDypBX2Oai+WKPdMQo9WOKydQ8U6Jpynz76ORxxsh+difTik1oNRbPXUZiisSeRnk1EpzqluG9RWT4N1yDxD4ctNQtgQrAoyt1VhwQa0041W2x3IrB7kNWZevT/AKS9VJ/9S/0NWL0n7S9VZ+YJO3BosSixB/yC4+OwqA4qaD/kGJ6YFQNzUjK1xkzQ8/xCrd//AMfDVUm5ng/3quX3/Hww+lBRUP3Sfap7mdVRUMG3CgGVW+9wOo7VCfut9KtRKHmRWAKnbkevShCLXiWeOeOweJw67NuR7Vxmv2NpqVuba/gWaFxgq3bnse1dV4it4rW+EEC7Igu4KOgJ61zuo/eXB7Uqrsi4aMo2iJHf2cSAhUdQvPYV2h/4/P8AgH9a4q1P/E0tef8AlqK7Q/8AH177P61jS2KqstrwuTTwSQc0wfdApU6VrYxbIZLZJOCKryabx+7kz7MK0BRQ0CZhz2DDIdB+BrG12z/0eEKDy+K7KXleaxNdXIthjrJ/SolFWNIy1OajtO20j3qPVbSd9Hv44A8jtA4CKMk8elb6xgcY/OtDS1C3kR9+o7Vzw1kbc1tT5S1mynjkSOWOQOBgqy4Yfga9L+DN+tvpN5bsrpKZt2Np5AUDNer+NL2OwhE3lq9ww2RrtBLMTwBWXo2lR2Nnm9Qy3czeZM4XJ3en0FehOKlCxPtESLfk9GGKlS8XPNeW/EOw1NvG9tJoltqG5408t1BCK/PboR65ru5LSZIotxxIFG4D1xziuGpTUdUy7Jm19oQ96ekik9awP3yY5Jpy3TocSA+9Y7CsdBkZ600kE9OKx1vhx81Tx3vAORTWoWNAE9M8fpVW5srWfPnW8bk98Ypq3anrgVJ5yEcYqlJx2EYN34O0edlZYWjZWDjaxIBBz0rf+2X8eC6wTr3K5jJ/mKFcE0E/hRKTloweu5Brt3DqHh+/sLi3nRpoWVflDDOMjke+KzfhFczweH57C/Xyp4JyURzglW54/HNafQ8VWuoUlx5ihj7iq05bBbSxY+I7f8Si1z3n/oa8+8QD/iUAYP8Aqen/AAKupurCK5iELmURqdwUOcA+wqhdaAk1uYFnfbjHzdQKunNRjYaRf0v/AI8oB/sCroFVreLyYkj67VxmrA7Csm7sGO6c9aKU9KKVwPlyj3q4tjJtycY70LbEk7QfxFes3Y6CnSNkYq+ttwcqSfani0x95fy5oUhXPWfhQMeGLfdx87nj61c8RzGe5Jzx0/Cq/wAPTs8MpnszHH41DfzebcNhsgdK45azHFaldRxXrPw41U3ujfZZWzNaYTPqp+6f6V5Gsqk7RwRXb/C6UprFzHk4aHOPof8A69KqrxHNaHc+Lbo2vh29kBw2wqPxrx1/EUmkaIzXcaTW8agIAuHGT0z3r0j4nXHleHwgJXe3WvAPHuo4sbSxQ9Rvcjv7VeFj7pzxVzfj8daLN/rDcQk/3osgfiDVuPxboRUE6hECexjb/CvHM0DGa7FFIvkR7QPF3h4DJvovwjbP8qSTxt4eiAxdM/tHCx/nXjP86XNOxPs0evN8QdCB+X7Vx6Q//XqGX4j6Sn+qt7uQn/ZVf5mvJqAaLIfs4np7fE23XmLS5WI6b5VA/QVWn+KFwQRBpUCn1eUt/ICvOs4pO/tTsNQidlc/EXW5ciIWsAPdI9x/U1lXPizXblSJdUuceikL/KsPGB60AYosPlRLPdXFw264uJpT1y7lv51GPY4+lIKPpQM93/Z2uGOk6xATlI5kdR6EjB/lXq6HOqW/pkV4b+zzdumrarak/u3hWQD3DY/rXt8Tf8Ta3/CsJ/EclVWkXb3BuZPrVWf/AFD/AENT3h/0lz71XuGxBIfaoMVoWLc/8SuP6CoWI9algONMj+gqsaTKI5P9fD/vVZvj/pDVUl5ng/3hVq+/4+G/CkMgJ+U/Q1aVtkgbg7QD/KqpPytn0qdgfm/3R/IU0Is+Jlla7hnkCgSRjGDmuZ1Dh1LdcV1viflLHJ/5Z1yWon94uP7tRW2LhuULY/8AE1tf+ugrtf8Al7/4B/WuLtQF1O095BXaY/0vP+x/WsqWxVQsZwop60wcpTk6VsYMfRSCloEI3I9KxNcPNqfST+lbT9KxNb+/aj/pp/Spl8LLhuRqM9cZq5pn/H5GDVIHgYqjrmtrodm0wybiRWSFR/eI4J9hkVyU03JG72EnkTW/FU9xw1ppmbeL0aXqzfh0/OtUDms/w5px0/RrdG++6729ST1J+tYnxO1XUNE0CK/0ucxSxzDeAgZXXHQ5HArvnFyVkYx1lY6zJxwTg9aheNWzuAP1rD8Balq2saCmo6x5A89iYVhjK4Tpzk10BrzZJxdmdDKrW0ZGNuKrSWAbI61o4pDTbQjFksOCNtUprJlGV3D610uMmmSIpXkA0kx3OY8uVDlWyKcs0gx8v1rca3RgcDFQyWmRxg07j0MwXfIyCKlS8B71JLZgA5Wqz2eDyDj1o6hoWVuVLY9eaR5gR71QaJ06E8VEzOOCOn607iL6uDx3pcnPHWqPnMCCeKkSbOeRTWoyyaFI2nnmoTN8uDUYkGaLCZcQ5zmioFl6c0UAeGbDg57U0IW6Yq68B3cdKcLcheBxXp3TNrsohD6CpVGTnGTVsQMAMjPFNEJBGAQaT8g1Ox8Nzm28LKSCC0jDI7DNRxkTOdv3uwFa3gqJJNG8qZQyM7DB6Gn614dl0xBf26O9gWwWHOw+/tXPdc2pcX0ONmumXXRbmJlAXls9TXonw0lVdfZc/M0LY/AiuNvrVbm6jmtkeaZuiIMk49AK6H4d+YfFUJ2lUSN8k8c46VpNXQ5/CdT8VTusLZS+yNSzO390Dqa+a/EWorqWpPJEpW3QbI1PXHqfc1658eNYm+yWltG+2KRmLEdTjpXh+fataEeWBjADQDzz0oPUUdua2LF7UdaQcUp+tMQnWjnNAHpSN2oGP7dqQ00HNL1HWgBaAaaP0p2Mjmi4C0U2nUNiPSfgLKE8YXEZ/wCWlo36EGvf4Mf2vb888V85/BOTy/HtsCfvwyLj8M/0r6Jtz/xN7cn8Kwnuc9bcv3RzcPn1qrc/6h/92rFyczvVW5P+jyf7tQznLUX/ACDY/oKrnvU0eP7Mj+gqA96QyGTP2m37DdVu9P79uPSqUh/0m35/iq3eHNy1AyE/dP0qzIfvf7uP5VVb7rfSrL9W+g/pRYRf8TnEdlj/AJ51yWoH94pHpXV+JxmOyA/551yd/wD6xeeMVNXYuHxFSzG7VrPOOXGK7M/8feR/d/rXG2Q/4m1p/wBdBXZH/j5Y/wCz/WsqWxdUsjhKcvIpin5achrVHOx1LSD6UUWEEn3axNb/ANZaf75/lW1J92sPXD81r6+ZSlsXDcgnaVFL28UcrryI5GKhvbI6Vy2pW48R+IdOljJggtyBc2sp+eMg5yD3U9M11Q+tZ1rp41TxXc4l8k2tvGwYDqzE9fbFZUHrY3lsdVe7S6eWAE2AAD0rG1vTLfWdMn0+93/Z5QA+xsHg54P4VdWKS2/cysG29MdAKHBxmuiq2o3OaD94q6fZw6fYwWdsCIIECJuOTgetSmnE00mvMb5ndnUNbrSHmnHmk6UgGkc02TtT8U1ulMCPGBSHmnHimtRYewwjr3qJgOc9/WpTTGA9KaJKzwox5GPpVOe3x0+hrQZSeR0qvNx9atDMp4ipxiozEcjFaBGc0xlzRsWZ5Qrn1pADV5owexqCSMg0xEIJxwelFPMZyTRUjPMlh3Enmjyh0BOK0fKC8jGKBFzyOK9FmlzOKj7uMCh13L7CrjwjOaVYSB7UvILnW+Cht0pFJ53H+ddvp0ryH7LLhrRwd0ZHBNcd4Sj26cgH9412mmcPHt6BhmuSq/eIk+pPpPh7TdJuJprKFlkkBBZmztHoPaqQ0a00i4utQgLGRlIVT/DnrXM6p4N8QHULi603XlTzHLKjF1xk9OOKyLxfHGmiOO+uFubdmx8rq5/kDVxi2txXvoc/8ZZEe203PXDfzryfBz1r0H4qXTTSaejn5khww9GJya8/J9q76asrFRVkIBQaM/LSDpVljiOKD0oBpOlACA4ofgU48CmNmgBBTgOeaYKk7cGmAmeOlOptLnAoAO9Lmmjjml70gO2+Dx/4uBpvBziT/wBANfR9uf8AibQV85fBzP8Awn2nt6LJ/wCgGvoq1I/tWH1rKoYVUaFyf37/AFqrcn9zJ64qxcH98/1qrc/6h/XFZyOVblqM/wDEti+gqA/WpY8DTYh7CoCcDJpA9yFzi6gHqwq3eHFw2e2Kpv8A8fdv/vCrV8f9JegoidsKc+lWHZTuKkEYHIOaozNmGTP9w/yqj4actYFc8DpSvqNLQ7DxAu5LP18uuR1Rdky59K7jUYGnS2KjIWPBNch4jt5IbmPcuE24BI4NOoroKb94yrEf8Ti0P/TQV16zRPdyxpIrSIPmUHlfrXIWP/IXtO43it/RI/P8UalG2VDMvI78VjTVkazVzZX7opyfWqt3ciyvXgmBcJ/d4z+dTW0omjEighSM4PWtbM59ycGjP50xTxTqBBJ92sPWuZLXI/jNbUhwtYutcvaf79TLSJcFqQjGaZ4H/eanrdwSTvn8sH2QAf404sFyx6AZqv4GXdp9oWZgZy8rYOD8zE1zUnZ3NpanQXx/0twPQVVftVq8iMc+S7PuH8QHFVJTgDPSuyr8JhFe8M5z1pD1pMYHNKMEda83Y6ELSE+lIcU1uRQApPYjrTSKO2TSZycdKErgNbnvTD3p560xh6UhjCeKaxzk0/ntTCB3qkIiY5HAOagmHyk1YY1XmJOelNDKxPOaYaVunXim5AOB+NU0O47tQwxzSAZFLnJwKVwGFQeooqUDA7UUBc898kHPNHkA8LmthIRnOwc1IYVHOAMeleincdzCMDA9OfSl8o9MH6CtvyQc4B5pgtwpywpLUGzotN0qTTLWAO24sNxxwAT2re0/iVAM9al01Bf6OikAyRgYplqpWQZ4x2NctdcrJvc0ZD8xx0rlfGVysEeT0jQvu9M10zGvM/i1fi2geMtgvgH2AFRR+IcVqeS+Lbg3c/2gsSM7R71zZPPFaF9IWt1jY8g55rPIFerHY1iGPUUdDx0oboPagdKoYcZozSdqDxQA4+9Rse1PJqM0AJSikpaBju1A5FIDQDzQA6lFNFO7UCOx+Esmzx9pv+1vX/x019G2jf8AE2h5r5p+GfmnxxpYt13TF2Cj1O019KaXZ363aSXUYwP4gRWNTcwqmjcH98+PWqt0f3EnPappmzM31qrdsq277mVcjGScVD1OVIvAgafFn0FVWZQOT+tZWp6ppgRI5NVBVAB5duhbn3PSsC41nS0+6t3Pg/xELTtc05GdbvVry3AIJ3AdauXxxdP29689j8Sw20yyW1ph1ORvl/ngUl342vJpGcRQLn0yaOVjUGdxKN8brnBYEA/WodItnsoZIpSCRxkdDXAv4u1Buksa+hCCon8V6i7EveEZPJUAUlErkdj6JtnZYo9vJ2DgjIPFRakkU9u6s8CEjpPjb+tfOl34y1CZNr6lcNgY4kI4/CucvNcM5/f3EknvI5bH51WglR1uexyrBp+rxS3t5YKsb5LR3ClQPTbkmpdN8TaHYeJZr1tQ823kAP7tGYhh2HHSvCG1WBG6gA+lRHX4F43ED61moK90a8vRnueu+M9Mu9RlmtVmdGxjcu3t6Gq9v47jhhEcdkSVGMtJjP6V4i3iSLJ2k/iKrt4o9AxzWlmJU0e5S+P5xxFawIfViTVSXx/qIPAtF/4Bn+teHS+JJ2PyA4+tQvrV3L9wZ9xQovqg5PI9wPxEv1P7w2jY9Y8f1prfEKK4kgF5bbQjZLRNn9DXidk+p6jeQ21ujNNM4RVxyzE4AruLP4c+Ky/+kxxwjv5sqjb+pqZQvoNqMT1m31ey1PT52srhJG8piV6MvB6irngfjS9IHU+SD+leLX2la14S1GGPUElhEhwkynKuO+GH8q9g+H13DdadYLCwY248p/Zh2rndLkJlrsdVqP8ArVPtVGfoDV+//wBav0rPuPujNaVvhZzQ3Id1NPOTzmkJXPHakyK85HSLuFLweh59KZ9aPpTAc3AzScZoJx34ppNIGKcdc00nrRjijsc0wGnpUb8HODmpT7UxzRYCF3CD5iBn1qvIQParEyh8bgDtORVW45ziqSAhfHamEUhOSDikBobKHdqQHHSjPOKULk0XuCHL60UKOfaiizAykg5w3HocU/yDnn5gKsBcEcZqSNST0Bz61282pBVW3DEAjgntUsNmrv8AvF49KvIgxj9anjQDbgU7g2aWht9mmUY/dnCn6Vf1C08i73KPkbkGs+BfkB7j0rp/J+26UhVS0qdMcmoqx5kQnZmGeOa5zxF4V07XnEt95m5QQAp4rs10e9YcwkD3IH9aP7DuWU52A+7f4VgoyTukXz2PAvFPw/tbfTriW1ndp41LksOuOwHavIm96+uda8O3HlS7mX7pPAJzx9K+UNUiMWoToQRhj1rvoNte8bRlcqEelJThnpSdq6Cw5HWjmgUuaAAnPSmN+tOzimN15oGJSiiigApQMUlL70AOHegUgOOKdQI6L4e3SWXjPSriRiqRykkjtwa+lLTU/taBoLkyL7Nivk60kaG4jkT7ynIrrtJ8Q3SzxxgsEchTuO0fnWc0ZzjzHvuv6qNI0qa8lwWXhQf4mPSvNLrXrnUW3yTF29AcAfQVR1LXb7V9JkssQyxwyZQh/m44PP8AFWTrNld+G72ATxu6PGsmMcjIzj0NTFGahZGhcX7KMbSG+tZ0+qlfvHaB71q67460260iO2OiQJdhR/pQyh/Fa4C5u7d2Jdnk5zxwKtRK16GzPr5jyVweaqya1cyDMaOeewNZjamV/wCPeGKI+oXJP41Cb+6J4mfd6Cq5UWka0l/qTgYgk+pFQ/ab+QEN0HUbsYrMaW5YnLyEnqCacltdS/KkcrfQGpSQWNLZeEfejGOc7+1VZ7eTcPMuIxnng5xUlvoOp3HKWs31KkVoQ+DtUk+9Fs92YChRSFsYbQxjnzwT34qBgMnac12EfgW8bG6aFfxJq3B4By6o95knsiZNNtId7HCADI3ZxVmJ4VP+rVv96u+HgC2iOJprkt/dZAv/ANercXgiKKESNbyPGD97nH50nIHJHApIpGYolBPouc0qiQOVhQn2xjmvZ/A3hrRX1WOG7so50YHg5616xp/hXRrF9+mWNvC57hRu/wDr0uYxlUUT5k8E6XqbeKtHmNrPtW8iLEocBdwyelfVOtJiSPI9aVbWRZ4yMYVgSOnGan8RhA8JU9QTUtmNSpz7HmXxI0K61y202O0aNfJnaRy5wMY7VZ+G9nHaWVs0ed9wzSSZPfkce3FbWqkCIfj/ACrM8BcWGmg/3T/M1hUlfQuL906q9/1q+mKzrz/Vr9a0L7/Wj6VnXx+RfrTqL3DGPxFXOBRkcZpuc9aM8156R0odnnIoz+dM78c0o5xRsMcTk0nel4ApM0CYufWqesXL2mlXlxFgyRRM6g9MirfqKzfEZVNA1EuMqIGJHqPSiOrGjmPDvj6DUJ4ba9tmguJCFVk+ZST0+ldq/GRXnPiS60a88R+GZdDeA7yvmCIYIwRgMPXrXozclq2rQUbWGyNuh7VVlI54qye9VZhkmskwRVbrzzTcU6QYOc/hSde1JoNg705etJzjjkCnZABYnCgZP0FNLUEOUcE4oryO48Q397rxl+1zQxF9qBGwFXPFFdP1eQ7HrywE4HBPWplgKnO2pohxVoD5TVdTFspBDjpz9asQxHv1p7cIccVPb9Fpphe5YgQjAAx+FbOkXEturhSv4rmsuM8LWhZ/xVpBkydjQl1O4CnEu3/dVV/kK5TUfHWnws8cutKHXqvmnP6Vs3fRvoa8JaNA7MEXcWbnHPU1adxRXNueh3eppe+XPBOZYnwysCcMK+d/H9qLXxRdqowpbcB7HmvYLEn+zDyeFavKPiUSfEr5/wCeSfyqo7nTSVjlPU0lKOlIK2NhOQacBTe4pV6GgAIOaYetSDpUbdaBiUUUtAABmlFIKDQAp5NOB4pg604daBD0JBBHarL30sqBHclR2pdJUNd4YAja/B/3aqL0FFhWLsOoTweWLZvLKNuVl6g13ltouq3dlGl3qDSIPnQMCdmeSB7e1ecgfMPrXqU1xMFiUSyY2gY3H0qWTIpXPhE3ADXl7I+O+wLioF8HafGw868fb3BxzVtXZ2QOxYe5zUvY/UVDbuShsegaDDzt3Htlyasx2ujqD5drG31Qt/Oqr8Dj1pjEgHBNK7A0/tNnEMQ2iY6fcApG1YoGKW4Cj3/wrPH3aWT/AFL0WsJnq+q+HrSxtrIo0jGaMO2498A/1rifE8sljdxRQP5aFN3TJ616jr/Nrpmf+eA/kK8u8cf8hSD/AK5f1NJ7mcHdmE93cM5/fOw9c4pbe7nilSWOaVZUO5XViCp9qr9lpU+5SW5tY3LnxHqd5J5t3IJn6EsoUt+VX9I12+s5/MsLjfGeZbG4OVb12N/Cf0rlx0/GpFJBBBIOae7JZ6n4ev8AR9Uv1ls1ax1NOXtJPlLe69j9RXoFtcpKuM4f+6a+ePEDEaQkwJE0ZVkkH3lPqD2r1zw5LJLottJK7vJszuY5P50jKpBHcLKej4fHr1p9yI7mPbtVj6Hg1m2LM0CFiScdzVhvu570zkehzfiOCNIli8wRzurlI5P4tq5OD34rL8FxtFa6WHUruiDD8Rmtj4iAHS9NcgbhcjB78o2al8KgN4U0diAWEK4J7cVlOK3NovQtX3+tHXpWZft8qema0r3/AFq/7tZt99yL6mnV+Bkw3KJP5U0mnHoajk7/AErgaOgeDx3pfxqMdPwpR938aTQ0S59TzSY+b1FJH1FKeOnrUj3HZ7isvxS4j8O6k7DcqwksPUdxWmn3PxqhryhtA1MMAR9nfgj2qobjS1OH1680bUfFXhqbQ2hb5lEvlrtK4IwGHr1r0STg5zivDPC//IzaV/13j/nXuMnT8a3ru9hzGkYFVpOQfpVo/dP0qrN92sEJFSQ5HNIKJep/CmnrTbHYkHIpsqGW3mjUZLoVHbqKVe1PHb600I8FvDJYTFXj2tGdpBGOaK921SztZrJ2mtoZG2A5eME9KK741HYq1z//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Internal rotation against resistance is among the exercises used to strengthen the subscapularis muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20706=[""].join("\n");
var outline_f20_14_20706=null;
var title_f20_14_20707="Kissing nevus";
var content_f20_14_20707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kissing nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nevus includes both the upper and lower eyelids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20707=[""].join("\n");
var outline_f20_14_20707=null;
var title_f20_14_20708="Vascular exclusion technique to control liver bleeding";
var content_f20_14_20708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Vascular exclusion technique to control liver bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 644px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascular exclusion occludes all the inflow and outflow vessels of the liver. As a result, venous return to the heart is severely reduced, which can lead to cardiac arrest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20708=[""].join("\n");
var outline_f20_14_20708=null;
var title_f20_14_20709="Ferrous fumarate: Pediatric drug information";
var content_f20_14_20709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferrous fumarate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"    see \"Ferrous fumarate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2373?source=see_link\">",
"    see \"Ferrous fumarate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Femiron&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferretts&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferro-Sequels&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferrocite&trade; [OTC];",
"     </li>",
"     <li>",
"      Hemocyte&reg; [OTC];",
"     </li>",
"     <li>",
"      Ircon&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Palafer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1013905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1013930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"      see \"Ferrous fumarate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (dose expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     iron):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommended Daily Allowance: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Daily Allowance of Iron:",
"      <b>",
"       (Dosage expressed as elemental iron)",
"      </b>",
"     </caption>",
"     <col align=\"left\" width=\"175\">",
"     </col>",
"     <col align=\"center\" width=\"175\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 to &lt;5 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5 mo to 10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Male",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         11-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         &gt;18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Female",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         11-50 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         &gt;50 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Treatment and prevention of iron deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe iron deficiency anemia: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to moderate iron deficiency anemia: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 1-2 mg elemental iron/kg/day up to a maximum of 15 mg elemental iron/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Iron deficiency: 2-3 mg/kg/day or 60-100 mg elemental iron twice daily up to 60 mg elemental iron 4 times/day, or 50 mg elemental iron (extended release) 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 60-100 mg elemental iron/day",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Iron Content of Iron Salts",
"     </caption>",
"     <col align=\"left\" width=\"220\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Iron Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Iron Content",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (% of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of iron salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous fumarate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         197",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         560",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         324",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate, exsiccated",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         217",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 324 mg [elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femiron&reg;: 63 mg [elemental iron 20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferretts&reg;: 325 mg [scored; elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrocite&trade;: 324 mg [contains tartrazine; elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemocyte&reg;: 324 mg [elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ircon&reg;: 200 mg [elemental iron 66 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferro-Sequels&reg;: 150 mg [contains sodium benzoate; elemental iron 50 mg; with docusate sodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1013935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not chew or crush sustained release preparations; administer with water or juice between meals for maximum absorption; may administer with food if GI upset occurs; do not administer with milk or milk products",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1013906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron deficiency anemias; supplemental therapy for patients receiving epoetin alfa",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dark stools, diarrhea, heartburn, nausea, staining of teeth, stomach cramping, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Contact irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1013908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component; hemochromatosis, hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5262760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using for longer than 6 months, except in patients with conditions that require prolonged therapy; avoid in patients with peptic ulcer, enteritis, or ulcerative colitis; avoid in patients receiving frequent blood transfusions. Severe iron toxicity may occur in overdose, particularly when ingested by children; iron is a leading cause of fatal poisoning in children; store out of children's reach and in child-resistant containers. Liquid preparations may temporarily stain the teeth.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1013909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain tartrazine which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1013922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milk, cereals, dietary fiber, tea, coffee, or eggs decrease absorption of iron.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5262763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum iron, total iron binding capacity, reticulocyte count, hemoglobin, ferritin",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1013924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Male: 75-175 mcg/dL; Female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1013923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is released from the plasma and eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5262762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1013925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Iron is absorbed in the duodenum and upper jejunum; in persons with normal iron stores 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores; food and achlorhydria will decrease absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Iron is largely bound to serum transferrin and excreted in the urine, sweat, sloughing of intestinal mucosa, and by menses",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1013937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2373?source=see_link\">",
"      see \"Ferrous fumarate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May color the stools and urine black; liquid preparations may temporarily stain the teeth; do not take within 2 hours of tetracyclines or fluoroquinolones, do not take with milk or antacids; keep out of reach of children",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5262765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When treating iron deficiency anemias, treat for 3-4 months after hemoglobin/hematocrit return to normal in order to replenish total body stores",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13054 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7C479FB97E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20709=[""].join("\n");
var outline_f20_14_20709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013905\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013930\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170746\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170733\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013935\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013906\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170797\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013908\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262760\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013909\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299322\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170742\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013922\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789285\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262763\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013924\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013923\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262762\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013925\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013937\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262765\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13054\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13054|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=related_link\">",
"      Ferrous fumarate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2373?source=related_link\">",
"      Ferrous fumarate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_14_20710="Benazepril and hydrochlorothiazide: Patient drug information";
var content_f20_14_20710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benazepril and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19767?source=see_link\">",
"     see \"Benazepril and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotensin HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benazepril, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ever had a very bad reaction called angioedema. Signs may be swelling of the hands, face, lips, eyes, tongue, or throat; trouble breathing; trouble swallowing; unusual hoarseness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking dofetilide.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This is not a list of all drugs or health problems that interact with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4201327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To lower the chance of feeling dizzy or passing out, rise slowly over a few minutes when sitting or lying down. Be careful climbing stairs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may affect certain lab tests. Be sure your doctor and lab workers know you take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you drink wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The chance of a very bad or sometimes deadly reaction called angioedema may be higher in black patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older, use this drug with care. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4193750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of fluid and electrolyte problems like mood changes, confusion, muscle pain or weakness, a heartbeat that does not feel normal, very bad dizziness or passing out, fast heartbeat, more thirst, seizures, feeling very tired or weak, not hungry, unable to pass urine or change in the amount of urine produced, dry mouth, dry eyes, or very bad upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4230803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Restlessness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4230804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug can cause certain eye problems. If left untreated, this can lead to lasting eyesight loss. If eye problems happen, signs like change in eyesight or eye pain most often happen within hours to weeks of starting this drug. Call your doctor right away if you have these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11203 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20710=[""].join("\n");
var outline_f20_14_20710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139518\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023481\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023483\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023482\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023487\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023488\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023490\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023485\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023486\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023491\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023492\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19767?source=related_link\">",
"      Benazepril and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_14_20711="Doxorubicin: Pediatric drug information";
var content_f20_14_20711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxorubicin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"    see \"Doxorubicin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/52/30533?source=see_link\">",
"    see \"Doxorubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adriamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adriamycin&reg;;",
"     </li>",
"     <li>",
"      Doxorubicin Hydrochloride Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Anthracycline",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"      see \"Doxorubicin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient's ideal weight should be used to calculate body surface area. Lower dose regimens should be given to patients with decreased bone marrow reserve, prior radiation therapy, or marrow infiltration with malignant cells.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 35-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose, repeat every 21 days; or 20-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly; or 60-90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     given as a continuous infusion over 96 hours every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose, repeat every 21 days; or 20-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2-3 days, repeat in 4 weeks or 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin 1.2-3 mg/dL: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;3 mg/dL: Reduce dose by 75%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 10 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 10 mg [contains lactose 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 20 mg [contains lactose 100 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 50 mg [contains lactose 250 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 2 mg/mL (5 mL, 10 mL, 25 mL, 75 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adriamycin&reg;: 2 mg/mL (5 mL, 10 mL, 25 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V. use only; reconstitute IVP doses with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to ensure isotonicity of the final solution; administer slow IVP at a rate no faster than over 3-5 minutes or by I.V. infusion over 1-4 hours at a concentration not to exceed 2 mg/mL, or by I.V. continuous infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F163205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, anidulafungin, aztreonam, bleomycin, caspofungin, chlorpromazine, cimetidine, cisplatin, cladribine, cyclophosphamide, dexamethasone sodium phosphate, diphenhydramine, doripenem, droperidol, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, gemcitabine, hydromorphone, leucovorin calcium, linezolid, lorazepam, melphalan, methotrexate, methylprednisolone sodium succinate, metoclopramide, mitomycin, morphine, ondansetron, oxaliplatin, paclitaxel, palonosetron, prochlorperazine edisylate, promethazine, ranitidine, sargramostim, sodium bicarbonate, teniposide, thiotepa, topotecan, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, gallium nitrate, ganciclovir, pemetrexed, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide, granisetron, heparin, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cyclophosphamide, droperidol, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, heparin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisplatin, cisplatin and mitomycin, fluorouracil, vinblastine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; store vials containing powder at room temperature, refrigerate vials containing liquid; reconstituted vials stable for 7 days at room temperature and 15 days if refrigerated and protected from light. Discard unused portion of preservative free injection vial. Incompatible with hydrocortisone, fluorouracil, furosemide, sodium bicarbonate, aminophylline, heparin, cephalothin, dexamethasone; unstable in solutions with a pH &lt;3 or &gt;7. Color change from red to purple indicates decomposition of drug.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of  acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin&rsquo;s disease, malignant lymphoma, soft tissue and bone sarcomas, thyroid cancer, small cell lung cancer, breast cancer, gastric cancer, ovarian cancer, bladder cancer, neuroblastoma, and Wilms' tumor [FDA approved in pediatrics (age not specified) and adults]; has also been used for the treatment of multiple myeloma, endometrial carcinoma, uterine sarcoma, head and neck cancer, liver cancer, and kidney cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DOXOrubicin may be confused with DACTINomycin, DAUNOrubicin, DAUNOrubicin liposomal,  doxapram, doxazosin, DOXOrubicin liposomal, epirubicin, IDArubicin, valrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Adriamycin PFS&reg; may be confused with achromycin, Aredia&reg;, Idamycin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Conventional formulation (Adriamycin PFS&reg;, Adriamycin RDF&reg;) may be confused with the liposomal formulation (Doxil&reg;)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use caution when selecting product for preparation and dispensing; indications, dosages and adverse event profiles differ between conventional DOXOrubicin hydrochloride solution and DOXOrubicin liposomal. Both formulations are the same concentration. As a result, serious errors have occurred.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ADR is an error-prone abbreviation",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxil&reg; may be confused with Doxal&reg; which is a brand name for doxepin in Finland, a brand name for doxycycline in Austria, and a brand name for pyridoxine/thiamine combination in Brazil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rubex, a discontinued brand name for DOXOrubicin in the U.S, is a brand name for ascorbic acid in Ireland",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F163204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute cardiotoxicity: Atrioventricular block, bradycardia, bundle branch block,  ECG abnormalities, extrasystoles (atrial or ventricular), sinus tachycardia, ST-T wave changes,  supraventricular tachycardia, tachyarrhythmia, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delayed cardiotoxicity: LVEF decreased, CHF (manifestations include ascites, cardiomegaly, dyspnea, edema, gallop rhythm, hepatomegaly, oliguria, pleural effusion, pulmonary edema, tachycardia); myocarditis, pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, photosensitivity, radiation recall, rash; discoloration of saliva, sweat, or tears",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, dehydration, infertility (may be temporary), hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, colon necrosis, diarrhea, GI ulceration, mucositis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia/neutropenia (nadir: 10-14 days; recovery: by day 21); thrombocytopenia and anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Skin &ldquo;flare&rdquo; at injection site, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, azoospermia, bilirubin increased, coma (when in combination with cisplatin or vincristine), conjunctivitis, fever, gonadal impairment (children), growth failure (prepubertal), hepatitis, hyperpigmentation (nail, skin &amp; oral mucosa), infection, keratitis, lacrimation, myelodysplastic syndrome, neutropenic fever, neutropenic typhlitis, oligospermia, peripheral neurotoxicity (with intra-arterial doxorubicin), phlebosclerosis, radiation recall pneumonitis (children), secondary acute myelogenous leukemia, seizure (when in combination with cisplatin or vincristine), sepsis, shock, Stevens-Johnson syndrome, systemic hypersensitivity (including urticaria, pruritus, angioedema, dysphagia, and dyspnea), toxic epidermal  necrolysis, transaminases increased, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxorubicin or any component; severe CHF, cardiomyopathy, pre-existing myelosuppression; patients who have received a total dose of 550 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     of doxorubicin or 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in patients with previous or concomitant treatment with daunorubicin, idarubicin, mitoxantrone, cyclophosphamide, or irradiation of the cardiac region; patients who have received previous treatment with complete cumulative doses of daunorubicin, idarubicin, or other anthracycline derivatives; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with impaired hepatic function",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"     <b>",
"      I.V. use only,",
"     </b>",
"     severe local tissue necrosis will result if extravasation occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . May cause severe myelosuppression; dose-limiting, primarily leukopenia and neutropenia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; irreversible myocardial toxicity, including potentially fatal CHF, may occur during therapy or months to years after therapy termination",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . The probability of developing myocardial toxicity is estimated to be 1% to 2% at a total cumulative dose of 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     of doxorubicin, 3% to 5% at a total cumulative dose of 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , 5% to 8% at a total cumulative dose of 450 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , and 6% to 20% at 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Myocardial toxicity may occur at lower cumulative doses in patients with prior mediastinal irradiation, concurrent cyclophosphamide therapy, or pre-existing heart disease. Pediatric patients are at increased risk for developing delayed cardiac toxicity and CHF during early adulthood due to an increasing census of long-term survivors; periodic long-term monitoring of cardiac function is recommended. Doxorubicin may contribute to prepubertal growth failure in pediatric patients. Secondary acute myelogenous leukemia and myelodysplastic syndrome have been reported following treatment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (moderate), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of DOXOrubicin. Management: Consider a doxorubicin dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution; increase monitoring for toxic effects of doxorubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May increase the serum concentration of DOXOrubicin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: DOXOrubicin may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May decrease the metabolism of DOXOrubicin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: DOXOrubicin may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenicity and embryotoxicity were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Advise patients to avoid becoming pregnant (females) and to avoid causing pregnancy (males) during treatment. According to the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, doxorubicin, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen, although chemotherapy should not be administered during the first trimester or after 35 weeks gestation.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, erythrocyte and platelet count; serum uric acid, echocardiogram, radionuclide left ventricular ejection fraction, liver enzymes, and bilirubin; observe I.V. injection site for infiltration and vein irritation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA and RNA synthesis by intercalating between DNA base pairs and by steric obstruction inducing DNA breaks; produces oxygen-free radicals which cause DNA denaturation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into breast milk; does not penetrate into CSF; distributes into cells rapidly with high concentrations in lung, kidney, muscle, spleen, and liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In both the liver and in plasma to both active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, triphasic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secondary: 3-3.5 hours for its metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 17-30 hours for doxorubicin and its metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Undergoes triphasic elimination; 40% to 60% eventually excreted in bile and feces; &lt;5% excreted in urine, primarily as unchanged drug and metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;2 years: 813 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;2 years: 1540 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/52/30533?source=see_link\">",
"      see \"Doxorubicin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transient red-orange discoloration of urine can occur for up to 48 hours after a dose; notify physician if fever, sore throat, bleeding, or bruising occurs; report any stinging sensation at the injection site during infusion. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 10-14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 21-28",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/14/20711/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ishii E, Hara T, Ohkubo K, et al, &ldquo;Treatment of Childhood Acute Lymphoblastic Leukemia With Intermediate Dose Cytosine Arabinoside and Adriamycin,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 1986, 14(2):73-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/14/20711/abstract-text/3458999 /pubmed\" id=\"3458999 \" target=\"_blank\">",
"        3458999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legha SS, Benjamin RS, Mackay B, et al, &ldquo;Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1982, 96(2):133-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/14/20711/abstract-text/7059060 /pubmed\" id=\"7059060 \" target=\"_blank\">",
"        7059060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13254 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20711=[""].join("\n");
var outline_f20_14_20711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708686\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163149\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163150\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047070\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047062\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163127\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163112\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047074\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163205\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047065\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047073\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163208\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163204\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047077\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047061\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047060\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163194\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163121\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163123\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163135\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047069\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047059\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047076\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047067\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047078\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13254\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13254|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=related_link\">",
"      Doxorubicin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/52/30533?source=related_link\">",
"      Doxorubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_14_20712="Neurofibromatosis type 2";
var content_f20_14_20712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurofibromatosis type 2",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/14/20712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20712/contributors\">",
"     D Gareth Evans, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/14/20712/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20712/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20712/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/14/20712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20712/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/14/20712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome that predisposes individuals to multiple tumors of the nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The most common of these are bilateral vestibular schwannomas; intracranial and spinal meningiomas and spine tumors are also a prominent component of this condition. Mutations in the NF2 gene, which produces merlin, a tumor suppressor, are responsible for this syndrome.",
"   </p>",
"   <p>",
"    The molecular pathogenesis, clinical features, diagnosis, and patient management of NF2 are reviewed here. Neurofibromatosis type 1 (NF1) (von Recklinghausen's disease) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NF2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis type II (NF2) is consistently linked with abnormalities of the NF2 gene, which is located on chromosome 22 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/4\">",
"     4",
"    </a>",
"    ]. The NF2 gene produces merlin, also known as schwannomin, a cell membrane-related protein that acts as a tumor suppressor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed molecular testing will identify an abnormality in NF2 in over 90 percent of families with multiple members affected with NF2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/7\">",
"     7",
"    </a>",
"    ]. For individuals thought to harbor a new de novo mutation, somatic mosaicism may prevent the molecular diagnosis from being established unless tumor tissue is analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of schwannomas and other tumors requires inactivation of both NF2 alleles, since tumors only develop in cells that have lost function of their normal NF2 allele. Individuals with NF2 may inherit an abnormal NF2 allele from a parent. Alternatively, a de novo mutation may take place after fertilization, resulting in a mosaic expression of two cell lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genotype phenotype correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within a family that includes multiple members with NF2, the phenotypic expression and natural history of the disease are similar. However, significant differences have been observed between families harboring different abnormalities of NF2.",
"   </p>",
"   <p>",
"    Frameshift or nonsense mutations cause truncated protein expression, which have been associated with more severe manifestations of NF2; missense or inframe deletions have been associated with milder manifestations of disease. In a detailed analysis of 268 patients in whom the NF2 abnormality was characterized, abnormalities manifested as a truncated protein were associated with statistically significant younger age at diagnosis, a higher prevalence and proportion of meningiomas, spinal tumors, tumors of cranial nerves other than VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with mutations causing truncated protein also had vestibular schwannomas at a younger age and had more cutaneous tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although NF2 was originally thought to be extremely rare, the use of detailed clinical criteria to identify cases, the recognition that greater than one-half of cases represent de novo mutations and occur in the absence of a positive family history, as well as the use of molecular testing to identify mutations within the NF2 gene, have led to increased recognition of this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ]. Two large population-based studies, one from England and the other from Finland, found that the incidence may be as high as 1 in 25,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome with multiple manifestations that is due to mutations in the NF2 gene. Patients typically present around 20 years of age.",
"   </p>",
"   <p>",
"    The most frequent clinical features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bilateral vestibular schwannomas, generally developing by 30 years of age - 90 to 95 percent",
"     </li>",
"     <li>",
"      Schwannomas of other cranial nerve - 24 to 51 percent",
"     </li>",
"     <li>",
"      Intracranial meningiomas 45 to 77 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Spinal tumors (both intramedullary and extramedullary) 63 to 90 percent",
"     </li>",
"     <li>",
"      Peripheral neuropathy - Up to 66 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cataracts - 60 to 81 percent",
"     </li>",
"     <li>",
"      Epiretinal membranes - 12 to 40 percent",
"     </li>",
"     <li>",
"      Retinal hamartomas - 6 to 22 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/15,17,22,23\">",
"       15,17,22,23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cutaneous tumors - 59 to 68 percent",
"     </li>",
"     <li>",
"      Skin plaques - 41 to 48 percent",
"     </li>",
"     <li>",
"      Subcutaneous tumors - 43 to 48 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children diagnosed with NF2 often have an atypical, but more severe, presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vestibular schwannomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular schwannomas in NF2 are typically bilateral and cause tinnitus, hearing loss, and balance dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/2\">",
"     2",
"    </a>",
"    ]. The onset of hearing loss is usually gradually progressive and leads to deafness, although sudden hearing loss can occur. The mechanism of hearing loss from vestibular schwannomas in NF2 is not well understood, and there is poor correlation between tumor size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth rate and degree of hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. One proposed mechanism is the accumulation of intralabyrinthine protein as a result of cochlear aperture obstruction, which can be visualized by high-resolution magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If left untreated, vestibular schwannomas can extend medially and cause brainstem compression and hydrocephalus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link&amp;anchor=H4#H4\">",
"     \"Vestibular schwannoma (acoustic neuroma)\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Almost all vestibular schwannomas in patients with NF2 are benign. However, they are an important cause of morbidity because of their anatomic location and bilaterality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meningiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of individuals with NF2 have meningiomas, and multiple meningiomas are often present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/30\">",
"     30",
"    </a>",
"    ]. The incidence increases with age, and lifetime risk may be as high as 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/17\">",
"     17",
"    </a>",
"    ]. Most meningiomas are intracranial, although intradural, extramedullary spinal meningiomas are also seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link&amp;anchor=H12#H12\">",
"     \"Meningioma: Clinical presentation and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H16#H16\">",
"     \"Spinal cord tumors\", section on 'Meningioma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with NF2 tend to develop meningiomas at an earlier age than those with sporadic meningiomas. When meningiomas are diagnosed during childhood, approximately 20 percent will be found to have NF2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/24,31\">",
"     24,31",
"    </a>",
"    ]. The meningiomas seen in patients with NF2 are more frequently atypical or anaplastic compared with sporadic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Meningiomas are less frequent with mutations of any type after exon 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Spinal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with NF2 eventually develop a spinal tumor, which can cause debilitating pain, muscle weakness, or paresthesias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/2,34,35\">",
"     2,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schwannomas are most common. These arise from the dorsal root and can take on a characteristic dumbbell shape. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H2#H2\">",
"       \"Spinal cord tumors\", section on 'Presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=see_link&amp;anchor=H9#H9\">",
"       \"Intradural nerve sheath tumors\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningiomas can also arise in the spinal cord in the extramedullary space. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H16#H16\">",
"       \"Spinal cord tumors\", section on 'Meningioma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intramedullary tumors, particularly ependymomas, are seen in 5 to 33 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H8#H8\">",
"       \"Spinal cord tumors\", section on 'Ependymomas'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathies can be manifested in a variety of ways in individuals with NF2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ]. Some people develop a mononeuropathy, often involving the facial nerve, which can precede the development of other NF2 manifestations. In 3 to 5 percent of adults, a more severe polyneuropathy not directly related to tumors is seen, and this can progress to severe muscle wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1,2,36\">",
"     1,2,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ophthalmic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NF2 may have visual impairment due to cataracts, optic nerve meningiomas, retinal hamartomas, and epiretinal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1,2,21,37\">",
"     1,2,21,37",
"    </a>",
"    ]. Cataracts are seen in 60 to 80 percent of cases and typically are manifested as posterior subcapsular lenticular opacities.",
"   </p>",
"   <p>",
"    Development of cataracts can lead to visual abnormalities in early childhood in those with an NF2 mutation. In addition, particular attention is required to differentiate optic nerve meningiomas or hamartomas from retinoblastoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of patients with NF2 have cutaneous manifestations, although only 10 percent have more than ten skin tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ]. These skin lesions can take several forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plaque-like lesions, which are intracutaneous and slightly raised. These may be more pigmented than the surrounding skin and may be associated with increased hair.",
"     </li>",
"     <li>",
"      Subcutaneous nodules can often be palpated, sometimes along the course of a peripheral nerve. These tumors represent a swelling of the nerve.",
"     </li>",
"     <li>",
"      Intracutaneous tumors, similar to those observed in patients with NF1, are also seen occasionally. These tumors generally represent schwannomas rather than neurofibromas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical criteria were initially established by an NIH consensus conference [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/38\">",
"     38",
"    </a>",
"    ]. These were subsequently modified into the Manchester criteria, which substantially improved the sensitivity for making the diagnosis without affecting specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/17,39\">",
"     17,39",
"    </a>",
"    ]. New criteria (the &ldquo;Baser&rdquo; criteria) appear to improve the diagnostic sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical diagnosis of NF2 is based upon the presence of ONE of the following criteria (",
"    <a class=\"graphic graphic_table graphicRef61129 \" href=\"UTD.htm?27/36/28235\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral vestibular schwannomas",
"      <br/>",
"     </li>",
"     <li>",
"      A first-degree relative with NF2 AND",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unilateral vestibular schwannoma OR",
"     </li>",
"     <li>",
"      Any two of the following: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unilateral vestibular schwannoma AND any two of the following: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities",
"      <br/>",
"     </li>",
"     <li>",
"      Multiple meningiomas AND",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unilateral vestibular schwannoma OR",
"     </li>",
"     <li>",
"      Any two of: schwannoma, glioma, neurofibroma, cataract",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical diagnosis can usually be confirmed by the identification of a pathogenic mutation of NF2 from the blood or by the identification of an identical mutation from two separate tumors in the same individual [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Screening for NF2",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high frequency of de novo NF2 cases, and patients may present before the clinical diagnostic criteria are fulfilled. Early identification of patients who have NF2 is important to minimize the complications associated with disease manifestations.",
"   </p>",
"   <p>",
"    Individuals who should be evaluated for NF2 should include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Individuals with a first degree relative with NF2 (ie, affected parent, sibling, or offspring)",
"      <br/>",
"     </li>",
"     <li>",
"      Those with multiple spinal tumors (schwannomas, meningiomas)",
"      <br/>",
"     </li>",
"     <li>",
"      Those with cutaneous schwannomas",
"      <br/>",
"     </li>",
"     <li>",
"      Those with an apparently sporadic vestibular schwannoma less than 30 years of age, or spinal tumor or meningioma less than 20 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of mutation screening for NF2 in those with a unilateral vestibular schwannoma is less certain. Although these patients appear to be at increased risk for the development of NF2, routine screening for germline mutations does not appear to be indicated except in those less than 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For individuals suspected of having NF2, the initial evaluation should include a detailed clinical and family history, careful cutaneous and eye examinations, and magnetic resonance imaging (MRI) of the craniospinal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ]. For individuals with a positive family history that includes identification of an NF2 mutation, molecular testing for that mutation is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major entities in the differential diagnosis of NF2 are sporadic vestibular schwannomas, neurofibromatosis type 1 (NF1), schwannomatosis and a familial syndrome of multiple meningiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sporadic vestibular schwannomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic vestibular schwannomas are relatively common in the general population. Although these tumors are unilateral, their diagnosis can cause confusion in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility that a unilateral vestibular schwannoma represents the first manifestation of NF2 is related to the age of the patient. For younger individuals who are less than 30 years of age, there is a substantial risk of developing a contralateral vestibular schwannoma, and patients should be monitored carefully for that possibility. Even with a negative family history these may represent a de novo somatic mutation with mosaicism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The likelihood that an individual diagnosed with a vestibular schwannoma after the age of 30 will have NF2 is minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neurofibromatosis type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;NF2 and NF1 are caused by mutations in genes on different chromosomes. Nonetheless, partial overlap in the clinical manifestations of these inherited disorders can occasionally lead to confusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key differences between NF1 and NF2 include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lisch nodules (raised, pigmented hamartomas of the iris) are characteristic of NF1 and are not seen in significant numbers in NF2.",
"     </li>",
"     <li>",
"      The schwannomas associated with NF2 rarely, if ever, undergo malignant transformation into a neurofibrosarcoma (malignant peripheral nerve sheath tumor).",
"     </li>",
"     <li>",
"      The \"dumbbell\" spinal root tumors that are seen with both NF2 and NF1 are schwannomas in NF2 and neurofibromas in NF1.",
"     </li>",
"     <li>",
"      NF2 is not associated with the cognitive impairment that is often seen with NF1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Schwannomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schwannomatosis is a rare autosomal dominant inherited condition. Patients with schwannomatosis can develop intracranial and peripheral schwannomas involving spinal roots, plexuses, and peripheral nerves but sparing the vestibular nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11731?source=see_link\">",
"     \"Overview of schwannomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Schwannomatosis is associated with mutations in the SMARCB1 gene, which is also located on chromosome 22. The schwannomas seen in this entity contain secondary mutations in the NF2 gene, but such mutations are not present in the germline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Familial meningioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial meningioma is a rare disorder with only a few families described in the literature. This entity is not associated with abnormalities of the NF2 gene.",
"   </p>",
"   <p>",
"    Multiple meningiomas usually occur in older adults. The occurrence of a single meningioma in a patient less than 25 years of age should prompt evaluation for an underlying genetic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PATIENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with NF2 is complex, and involves multiple disciplines to prevent or treat the various complications that may develop. Whenever possible, patients should be cared for by a multidisciplinary team with expertise in the care of NF2 affected individuals and families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment of vestibular schwannomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment for vestibular schwannomas in individuals with NF2 is preservation of function and maintenance of quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ]. As such, the identification of a tumor per se is not an indication for treatment and the potential benefits must be balanced against the risks of active intervention.",
"   </p>",
"   <p>",
"    Treatment is generally indicated when there is a risk of brainstem compression, deterioration of hearing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    facial nerve dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/2\">",
"     2",
"    </a>",
"    ]. If treatment is required in patients with NF2, vestibular schwannomas are generally managed surgically. In this setting, surgery can be more complex than with sporadic tumors, since NF2 tumors are often multifocal. These tumors may extend to involve fibers of the facial nerve and there is a significant risk of damage to the facial nerve during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ]. This is particularly problematic, since the facial nerve controls the blink reflex and innervates the lacrimal gland. Loss of the blink reflex or loss of tearing may complicate other eye problems. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Ophthalmic manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery and stereotactic radiotherapy have become important modalities in the treatment of appropriately selected patients with sporadic vestibular schwannomas. Such patients are generally much older than those with NF2 and have unilateral tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of radiation therapy in managing vestibular schwannomas in patients with NF2 is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Reports using radiation in patients with NF2 have shown variable outcomes, and long-term follow-up is lacking. Furthermore, surgical resection may be more difficult following stereotactic radiosurgery. There are also concerns that such patients may have an increased risk of secondary malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The risk of second malignancies may also be increased with fractionated radiation therapy, with one report of a rhabdomyosarcoma occurring in the radiation field in an NF2 patient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with severe hearing impairment, strategies such as cochlear or brainstem implants may offer some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=see_link&amp;anchor=H11#H11\">",
"     \"Hearing amplification in adults\", section on 'Cochlear implants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Meningioma management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas can arise both at intracranial sites and as intradural, extramedullary sites in the spinal cord. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link&amp;anchor=H12#H12\">",
"     \"Meningioma: Clinical presentation and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meningiomas are managed surgically when possible in patients with NF2. Radiation therapy has been used in patients whose tumors are not surgically accessible or in those in whom only a partial resection is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/54\">",
"     54",
"    </a>",
"    ]. However, long-term follow-up is lacking in this population. As with the use of radiation in patients with vestibular schwannomas, there is concern about the development of secondary neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H16#H16\">",
"     \"Spinal cord tumors\", section on 'Meningioma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intramedullary spinal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 75 percent of intramedullary spinal tumors are grade I or II ependymomas. These are often diagnosed with screening imaging studies and usually grow very slowly without symptoms for a prolonged period. Careful neurologic surveillance for evidence of progression is indicated in this situation. If symptoms require intervention, which is relatively uncommon, treatment is generally surgical resection rather than radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NF2 gene product appears to affect multiple molecular pathways involved in cell growth. An understanding of this provides a potential opportunity for targeted therapy in the treatment of NF2-related tumors. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    induced tumor regression of at least 40 percent in 12 patients extended to 55 percent of 31 patients with progressing vestibular schwannomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Improvements in hearing were noted in 57 percent of ears associated with target vestibular schwannomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     NF2 positive family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;For families in which there is documented index case of NF2, screening of at-risk family members is important so that a diagnosis can be established in affected individuals as early as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a specific mutation has been identified in the index case, this information provides a 100 percent specific marker to test other family members. Prenatal testing is possible in settings where a known mutation has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/2\">",
"     2",
"    </a>",
"    ]. However, mutation screening is not 100 percent sensitive in patients with NF2.",
"   </p>",
"   <p>",
"    For individuals known to harbor an NF2 mutation, follow-up should include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Annual hearing evaluation, including brainstem auditory evoked response",
"      <br/>",
"     </li>",
"     <li>",
"      Ophthalmologic evaluation",
"      <br/>",
"     </li>",
"     <li>",
"      Cutaneous examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Craniospinal MRI, beginning at age 10 to 12 years, repeated every two years for those less than 20 years old and every three to five years after age 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"       1",
"      </a>",
"      ]. If tumors are detected, the frequency of testing should be performed annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children who have not inherited NF2, no further testing or prospective evaluation is necessary. A detailed protocol for at risk relatives has recently been published [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals typically present with symptoms due to the NF2-related tumors around age 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/17\">",
"     17",
"    </a>",
"    ]. The diagnosis of NF2 in children is often delayed, since the earliest manifestations may be skin tumors and ocular findings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/24,58\">",
"     24,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite surveillance for the development of tumors in patients with NF2 and the aggressive management of any abnormalities that are detected, NF2 is associated with substantial morbidity and shortened survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vestibular schwannomas associated with NF2 are more difficult to manage than their sporadic counterparts. In NF2 the lesions are often multifocal, and histologically, these are less vascular and more lobular [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/59\">",
"       59",
"      </a>",
"      ]. Because of this and the bilaterality of the tumors, the majority of patients eventually become completely deaf.",
"     </li>",
"     <li>",
"      Poor balance due to eighth nerve involvement, visual problems, and muscle weakness can all contribute to immobility and many patients become wheelchair bound in early adulthood.",
"     </li>",
"     <li>",
"      Overall survival appears to be shortened in patients with NF2 due to complications of their tumors. In studies from the 1970s and 1980s, the actuarial survival after establishing the diagnosis was 15 years, with an average age at death of 36 years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/17,60,61\">",
"       17,60,61",
"      </a>",
"      ]. Earlier diagnosis and improved improvements in treatment may have improved outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20712/abstract/41,62\">",
"       41,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/20/44353?source=see_link\">",
"       \"Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome that causes multiple tumors of the nervous system in affected individuals. NF2 is due to abnormalities in the NF2 gene, which produces merlin, a cell membrane-related protein that acts as a tumor suppressor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Molecular pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of NF2 include bilateral vestibular schwannomas in almost all patients. Other commonly observed nervous system tumors include intracranial meningiomas, schwannomas of other cranial nerves, and spinal tumors (especially schwannomas of the dorsal nerve roots, meningiomas, and ependymomas). Neuropathies and ocular and cutaneous manifestations are also frequent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of NF2 is based upon the National Institutes of Health consensus criteria as subsequently modified in the Manchester criteria (",
"      <a class=\"graphic graphic_table graphicRef61129 \" href=\"UTD.htm?27/36/28235\">",
"       table 1",
"      </a>",
"      ). The differential diagnosis includes sporadic unilateral vestibular schwannomas, neurofibromatosis type 1, schwannomatosis, and familial meningiomas. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the management of the various manifestations of NF2 is similar to that for sporadic tumors of the same type, multidisciplinary team management is required to minimize disabilities and avoid potential morbidity caused by treatment. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patient management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/1\">",
"      Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 4:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/2\">",
"      Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 2009; 11:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/3\">",
"      Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009; 373:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/4\">",
"      Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986; 322:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/5\">",
"      Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/6\">",
"      Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/7\">",
"      Evans DG, Ramsden RT, Shenton A, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007; 44:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/8\">",
"      Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003; 40:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/9\">",
"      Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003; 40:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/10\">",
"      Evans DG, Wallace AJ, Wu CL, et al. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998; 63:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/11\">",
"      Selvanathan SK, Shenton A, Ferner R, et al. Further genotype--phenotype correlations in neurofibromatosis 2. Clin Genet 2010; 77:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/12\">",
"      Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005; 26:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/13\">",
"      Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/14\">",
"      Antinheimo J, Sankila R, Carp&eacute;n O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000; 54:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/15\">",
"      Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994; 52:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/16\">",
"      Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996; 38:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/17\">",
"      Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/18\">",
"      Smith MJ, Higgs JE, Bowers NL, et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 2011; 48:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/19\">",
"      Bosch MM, Boltshauser E, Harpes P, Landau K. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 2006; 141:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/20\">",
"      Ragge NK, Baser ME, Riccardi VM, Falk RE. The ocular presentation of neurofibromatosis 2. Eye (Lond) 1997; 11 ( Pt 1):12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/21\">",
"      Ragge NK, Baser ME, Klein J, et al. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol 1995; 120:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/22\">",
"      MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 1998; 5:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/23\">",
"      Mautner VF, Lindenau M, Baser ME, et al. Skin abnormalities in neurofibromatosis 2. Arch Dermatol 1997; 133:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/24\">",
"      Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999; 81:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/25\">",
"      Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996; 106:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/26\">",
"      Fisher LM, Doherty JK, Lev MH, Slattery WH. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium. Otol Neurotol 2009; 30:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/27\">",
"      Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 2004; 25:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/28\">",
"      Graamans K, Van Dijk JE, Janssen LW. Hearing deterioration in patients with a non-growing vestibular schwannoma. Acta Otolaryngol 2003; 123:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/29\">",
"      Asthagiri AR, Vasquez RA, Butman JA, et al. Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One 2012; 7:e46132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/30\">",
"      Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol 2010; 99:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/31\">",
"      Evans DG, Watson C, King A, et al. Multiple meningiomas: differential involvement of the NF2 gene in children and adults. J Med Genet 2005; 42:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/32\">",
"      Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001; 60:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/33\">",
"      Larson JJ, van Loveren HR, Balko MG, Tew JM Jr. Evidence of meningioma infiltration into cranial nerves: clinical implications for cavernous sinus meningiomas. J Neurosurg 1995; 83:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/34\">",
"      Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001; 218:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/35\">",
"      Dow G, Biggs N, Evans G, et al. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2005; 2:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/36\">",
"      Sperfeld AD, Hein C, Schr&ouml;der JM, et al. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002; 125:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/37\">",
"      McLaughlin ME, Pepin SM, Maccollin M, et al. Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 2007; 125:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/38\">",
"      Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988; 45:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/39\">",
"      Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/40\">",
"      Baser ME, Friedman JM, Joe H, et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med 2011; 13:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/41\">",
"      Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005; 19:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/42\">",
"      Evans DG, Raymond FL, Barwell JG, Halliday D. Genetic testing and screening of individuals at risk of NF2. Clin Genet 2012; 82:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/43\">",
"      Evans DG, Ramsden RT, Gokhale C, et al. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet 2007; 71:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/44\">",
"      Mohyuddin A, Neary WJ, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002; 39:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/45\">",
"      Kida Y, Kobayashi T, Tanaka T, Mori Y. Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol 2000; 53:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/46\">",
"      Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007; 60:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/47\">",
"      Roche PH, R&eacute;gis J, Pellet W, et al. [Neurofibromatosis type 2. Preliminary results of gamma knife radiosurgery of vestibular schwannomas]. Neurochirurgie 2000; 46:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/48\">",
"      Rowe JG, Radatz MW, Walton L, et al. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 2003; 74:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/49\">",
"      Baser ME, Evans DG, Jackler RK, et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 2000; 82:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/50\">",
"      Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/51\">",
"      Balasubramaniam A, Shannon P, Hodaie M, et al. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol 2007; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/52\">",
"      Carlson ML, Babovic-Vuksanovic D, Messiaen L, et al. Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg 2010; 112:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/53\">",
"      Neff BA, Wiet RM, Lasak JM, et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope 2007; 117:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/54\">",
"      Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys 2009; 73:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/55\">",
"      Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/56\">",
"      Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/57\">",
"      Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/58\">",
"      Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 2005; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/59\">",
"      Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 1993; 52:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/60\">",
"      Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992; 29:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/61\">",
"      Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 1992; 29:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20712/abstract/62\">",
"      Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71:715.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5206 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-ADE86C94E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20712=[""].join("\n");
var outline_f20_14_20712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NF2 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genotype phenotype correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vestibular schwannomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meningiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Spinal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ophthalmic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Screening for NF2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sporadic vestibular schwannomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neurofibromatosis type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Schwannomatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Familial meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment of vestibular schwannomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Meningioma management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intramedullary spinal tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NF2 positive family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/36/28235\" title=\"table 1\">",
"      Diagnostic criteria NF2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28694?source=related_link\">",
"      Intradural nerve sheath tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11731?source=related_link\">",
"      Overview of schwannomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/20/44353?source=related_link\">",
"      Patient information: Vestibular schwannoma (acoustic neuroma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_14_20713="Mucinous neoplasm panc Gross I";
var content_f20_14_20713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58137%7EGAST%2F66804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58137%7EGAST%2F66804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic mucinous cystic neoplasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen of a mucinous cystic neoplasm consisting of multiple cystic spaces.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pancreatic mucinous cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross appearance of a mucinous cystadenoma of the pancreas and attached spleen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael L Steer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20713=[""].join("\n");
var outline_f20_14_20713=null;
var title_f20_14_20714="Vulvar cancer: Staging, treatment, and prognosis";
var content_f20_14_20714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vulvar cancer: Staging, treatment, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20714/contributors\">",
"     John C Elkas, MD, JD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/14/20714/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/14/20714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer is the fourth most common gynecologic cancer (following cancer of the uterine corpus, ovary, and cervix) and comprises 5 percent of malignancies of the female genital tract [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/1\">",
"     1",
"    </a>",
"    ]. Annually in the United States, there are an estimated 4700 new cases and 990 deaths from this disease.",
"   </p>",
"   <p>",
"    The staging, treatment, and prognosis of women with vulvar cancer are discussed here. The clinical presentation, diagnosis, and pathology of vulvar cancer and the techniques for surgical treatment and radiation therapy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4936?source=see_link\">",
"     \"Radical vulvectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link\">",
"     \"Overview of radiation therapy for gynecologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer is surgically staged based on pathologic evaluation of a vulvar biopsy and inguinofemoral lymph nodes. Prior to a complete staging procedure, however, a clinical evaluation helps guide the surgical and medical approach (eg, choice of surgical incision, use of neoadjuvant chemoradiation).",
"   </p>",
"   <p>",
"    A complete pelvic and general physical examination is performed, with particular attention to measurement of the diameter of the primary tumor and palpation for inguinal, axillary, or supraclavicular lymphadenopathy.",
"   </p>",
"   <p>",
"    We do cervical cytology and colposcopy of the cervix, vagina, and vulva because of the multifocal nature of squamous intraepithelial lesions in these areas. Screening for other cancers is performed according to age-appropriate guidelines. This is particularly important in women with vulvar cancers since some of these patients have an increased frequency of synchronous epithelial neoplasms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with large tumors (ie, &ge;2 cm) or suspected metastases, an",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    computed tomography may be performed to detect lymphadenopathy or other metastases; additional radiographic and endoscopic studies are performed as appropriate.",
"   </p>",
"   <p>",
"    In addition, women should undergo evaluation of medical status prior to surgery, chemotherapy, or radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24201?source=see_link\">",
"     \"Preoperative management of patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staging and primary surgical treatment are typically performed as a single procedure. Staging takes into account the most important factors related to prognosis: tumor size, depth of invasion, lymph node involvement, and presence of distant metastases.",
"   </p>",
"   <p>",
"    The International Federation of Gynecology and Obstetrics (FIGO) and TNM staging use a surgical-pathologic staging system for vulvar cancer based upon findings from the biopsy of the vulvar lesion(s) and the inguinofemoral lymph nodes (",
"    <a class=\"graphic graphic_table graphicRef50726 \" href=\"UTD.htm?11/28/11726\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Of note, much of the published data are based upon a clinical staging system in use prior to 1988.",
"   </p>",
"   <p>",
"    Surgical staging is preferable because inguinofemoral lymph node status is the most important predictor of overall prognosis (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Prognosis'",
"    </a>",
"    below). Palpation of the groin is inadequate; of patients with clinically normal lymph nodes, 16 to 24 percent have metastases, while 24 to 41 percent of those with clinically enlarged nodes are negative at histological examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Clinical assessment is combined with additional information (imaging, prognostic factors related to the primary lesion [eg, diameter, depth], or fine needle aspiration) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical alternatives to radical vulvectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, all patients with vulvar cancer were staged and treated with radical vulvectomy and en bloc inguinofemoral lymph node dissection (LND), a procedure associated with high rates of survival as well as morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4936?source=see_link\">",
"     \"Radical vulvectomy\"",
"    </a>",
"    .) Current approaches individualize treatment so that the most conservative procedure is used to optimize survival while minimizing perioperative morbidity and maximizing long-term psychosexual and physical well being [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard radical vulvectomy consists of removal of the entire vulva down to the level of the deep fascia of the thigh, the periosteum of the pubis, and the inferior fascia of the urogenital diaphragm. This was traditionally performed through a single incision that circumscribes the labia majora and extends to the groins bilaterally to include en bloc inguinofemoral LND (",
"    <a class=\"graphic graphic_figure graphicRef75367 \" href=\"UTD.htm?23/57/24465\">",
"     figure 1",
"    </a>",
"    ). Morbidity associated with this procedure includes wound breakdown, psychosexual effects from distortion of the vulva, and lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4936?source=see_link\">",
"     \"Radical vulvectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative surgical approaches that remove less of the vulvar and surrounding skin are most commonly performed. However, the depth of the dissection is the same as in standard radical vulvectomy (from the skin to the urogenital diaphragm) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/15\">",
"     15",
"    </a>",
"    ]. For all types of vulvar excision, a tumor-free margin of at least a 1 cm is appears to decrease the risk of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. For example, a retrospective case series (n = 135) reported a decrease in the rate of local recurrence in cases with a normal tissue margin of &ge;1 cm compared with &lt;8 mm (0 versus 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Radical local excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies in women with stage I or II disease, radical local excision or radical partial vulvectomy (ie, removal or part or all of the vulva unilaterally, terminology also includes radical hemivulvectomy and modified radical vulvectomy) compared with radical vulvectomy in stage I disease yielded similar rates of local recurrence (7.2 versus 6.3 percent) with less morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/21\">",
"     21",
"    </a>",
"    ]. There are no randomized trials comparing radical local excision to radical vulvectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Three-incision technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to radical vulvectomy in women with stage III or IV disease is the three-incision technique. This technique allows for radical excision of the primary lesion and bilateral groin node evaluation while retaining skin over the groin (",
"    <a class=\"graphic graphic_figure graphicRef67561 \" href=\"UTD.htm?28/5/28754\">",
"     figure 2",
"    </a>",
"    ). This skin bridge decreases risk of postoperative wound breakdown and lower extremity lymphedema and improves cosmesis.",
"   </p>",
"   <p>",
"    According to observational data, it appears that the three-incision technique compared with standard radical vulvectomy is associated with similar rates of disease-free and overall survival in patients with T1 or T2 lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ]. Margins &lt;1 cm may increase the risk for recurrence in the skin bridge; such recurrences are typically fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Coexistent precancerous lesions or dermatoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer may coexist with vulvar or vaginal intraepithelial neoplasia or dermatoses (eg, lichen sclerosus). At the time of surgical treatment or staging, intraepithelial neoplasia should be excised, but it is not necessary to excise benign lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inguinofemoral lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inguinofemoral LND (ie, removal of the superficial inguinal and deep femoral lymph nodes) (",
"    <a class=\"graphic graphic_figure graphicRef67561 \" href=\"UTD.htm?28/5/28754\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74932 \" href=\"UTD.htm?36/23/37233\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76021 \" href=\"UTD.htm?32/28/33227\">",
"     table 2",
"    </a>",
"    ), is performed for all stages of disease except stage IA. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Stage I'",
"    </a>",
"    below.) Pelvic LND (ie, removal of the obturator and iliac nodes) is not required for staging or therapy (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Adjuvant RT for node positive patients'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Morbidity rates are high after inguinofemoral LND, including wound infection and breakdown (20 to 40 percent) and lower extremity lymphedema (30 to 70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/5,24,25\">",
"     5,24,25",
"    </a>",
"    ]. Some have proposed nodal debulking rather than full LND followed by groin irradiation to minimize morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Unilateral versus bilateral lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of approach for LND depends on the size and location of the lesion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LND is optional for stage IA disease (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Stage I'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Unilateral LND was associated with a &lt;1 percent risk of contralateral groin node metastases in multiple observational studies for stage IB disease that meets all the following requirements [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/5,27\">",
"       5,27",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unifocal",
"     </li>",
"     <li>",
"      Lateral (&gt;1 cm from the vulvar midline)",
"     </li>",
"     <li>",
"      Not located in the anterior portion of the labia minora (defined anatomically as the area just posterior to the clitoris) as this area may have contralateral lymph flow [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      No palpable lymphadenopathy in either groin",
"     </li>",
"     <li>",
"      No lymph node metastases found at time of unilateral LND",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral LND is performed for stage II or greater disease and for stage IB disease that is central (&lt;1 cm from the vulvar midline) or if lymph node metastases are discovered at unilateral LND. The rate of bilateral groin metastases in women with lesions with unilateral lesions with stromal invasion &ge;3 mm is 2.8 percent or higher [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Superficial versus deep lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inclusion of deep LND is generally preferred. Data are limited to one prospective study in which women with stage I disease treated with superficial inguinal LND had a high rate of groin recurrence (6 of 121 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, some data suggest that the removal of a greater number of nodes is associated with improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sentinel node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sentinel lymph node biopsy (SLNB) is under investigation as an alternative to inguinofemoral LND [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/8\">",
"     8",
"    </a>",
"    ]. Ideally, this approach would incur less morbidity without compromising detection of lymph node metastases or increasing the risk of a groin recurrence. There is little margin for error in choosing an alternative approach because groin recurrence in vulvar cancer is usually fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials comparing SLNB to traditional inguinofemoral LND, but multiple case series have been published. Efforts are ongoing to improve the accuracy of SLNB, including identifying the most effective approach to lymphatic mapping and investigating the use of advanced pathologic methods to detect micrometastases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the sentinel lymph node (SLN) hypothesis, tumor cells migrate from a primary tumor and colonize one or a few lymph nodes (ie, the SLN) before involving other lymph nodes. Peritumoral injection of a dye or tracer permits identification of a SLN in most patients, and its status accurately predicts the status of the remaining regional nodes. The concept of lymphatic mapping and SLNB was initially developed for penile cancer and has been extensively studied in melanoma and breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first area to receive lymphatic drainage from a lateral vulvar lesion is usually the ipsilateral superficial inguinal nodes. At least in theory, if the SLN shows no evidence of metastatic involvement, then all other nodes should be negative, rendering complete nodal dissection unnecessary.",
"   </p>",
"   <p>",
"    The best candidates for intraoperative lymphatic mapping are women with uninfected tumors limited to the lateral vulva, with no palpable enlarged groin nodes and no history of vulvar surgery that could disrupt lymphatic drainage.",
"   </p>",
"   <p>",
"    Bilateral groin involvement is common in patients with midline vulvar cancers, even if drainage to the contralateral groin is not observed on lymphoscintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/35\">",
"     35",
"    </a>",
"    ]. SLNs should be detected bilaterally when the lesion is midline; if a SLN is not found on each side, then a full inguinofemoral LND would be required on the side without the SLN [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraoperative lymphatic mapping of SLN is performed using either of two general methods: peritumoral injection of isosulfan blue dye or preoperative lymphoscintigraphy using radiolabeled colloid followed by node detection with an intraoperative gamma-detecting probe. Use of a combination of blue dye and radiolabeled colloid is preferred so as to yield more accurate results than either test alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/7,37-42\">",
"     7,37-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, the procedures used for administration and node detection with blue dye versus radiolabeled colloid differ. Blue dye is injected and detected intraoperatively. However, this technique require a skin incision approximately the same size as that for LND to allow dissection down to Camper's fascia and identification of the blue afferent channel to the blue SLN. Conversely, radiolabeled colloid must be administered preoperatively (which adds an additional preoperative step and may cause additional patient discomfort), but intraoperatively it allows a smaller groin node incision (2 cm).",
"   </p>",
"   <p>",
"    Histopathological lymph node examination in vulvar cancer is not standardized. While some data appear to support serial sectioning and immunostaining (ie, ultrastaging) of SLNs to search for micrometastases, the optimal method (standard hematoxylin and eosin versus ultrastaging) remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. However, the prognostic significance of a metastasis found on ultrastaging and the treatment implications are unclear as studies have not evaluated outcome when metastasis have been found this way.",
"   </p>",
"   <p>",
"    Results from observational studies suggest that SLNB is a sensitive method for detecting groin lymph node metastases and is superior to other alternatives to inguinofemoral LND. However, studies are limited because many did not follow a SLNB with complete node dissection and so sensitivity could not be appropriately calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, it is generally accepted that there is a learning curve in performing the SLN procedure, thus results may be affected by series performed by less experienced operators or early cases within a series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Representative observational studies are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A metaanalysis of observational studies compared the following approaches of detecting lymph node metastases in women with vulvar cancer: SLNB (using blue dye or technetium-99m-labelled nanocolloid), groin ultrasonography with or without fine needle aspiration, computed tomography, magnetic resonance imaging, and positron emission tomography [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/8\">",
"       8",
"      </a>",
"      ]. The most accurate tests were SLNB with either technetium (sensitivity 97 percent, 95% CI 91-100; negative likelihood ratio 0.12, 95% CI 0.053-0.28) or blue dye (sensitivity 95 percent, 95% CI 82-99; negative likelihood ratio 0.16, 95% CI 0.07-0.32). Sensitivities for the other tests ranged from 45 to 86 percent.",
"     </li>",
"     <li>",
"      In the largest observational study, 403 women with squamous cell vulvar cancer (tumor size &lt;4 cm) had sentinel node detection with a combination of radioactive tracer and blue dye [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/48\">",
"       48",
"      </a>",
"      ]. The sentinel node was then removed and ultrastaged. If a SLN was detected and was negative (n = 276), no further treatment was given. If a SLN was detected and was positive or if no SLN was detected, inguinofemoral LND was performed. Median follow-up was 35 months.",
"      <br/>",
"      <br/>",
"      The groin recurrence rate in women with a negative SLNB in all study participants was 2.9 percent. The reported rate of groin recurrence after inguinofemoral LND ranges from 1 to 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/5,6,16,31,49-52\">",
"       5,6,16,31,49-52",
"      </a>",
"      ]. Median time to groin recurrence was 12 months. Data were not reported for patients who had undergone LND.",
"     </li>",
"     <li>",
"      A Gynecology Oncology Group study (n = 452) compared SLNB to inguinofemoral LND in women with squamous vulvar cancer with at least 1 mm invasion and tumor size &ge;2 cm and &le;6 cm. The sensitivity of SLNB was 92 percent and the negative predictive value was 96 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data are promising, but limited, and SLNB for vulvar cancer is still appropriate only for investigational use, not clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF SQUAMOUS CELL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical wide excision and selective inguinal LND characterize the main approach to patients with early stage disease. Chemoradiation is an alternative to radical vulvectomy with en bloc inguinofemoral LND for advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Early stage disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stage I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I disease is subdivided according to depth of stromal invasion; lesions with &le;1 mm of stromal invasion are categorized as stage IA, or T1a, and with &gt;1 mm of stromal invasion as stage IB, or T1b disease (",
"    <a class=\"graphic graphic_table graphicRef50726 \" href=\"UTD.htm?11/28/11726\">",
"     table 1",
"    </a>",
"    ). Patients with stage IA disease have a low risk of groin recurrence and very low rates of groin node metastases (see below); therefore, it is reasonable to omit groin treatment for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/19,54,55\">",
"     19,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage IA &mdash; Radical local excision without LND is the treatment of choice in patients with less than 1 mm of stromal invasion, since inguinofemoral lymph node metastases are rare (&lt;1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stage IB &mdash; For lesions with &ge;1 mm of stromal invasion, the risk of inguinofemoral lymph node metastases is &ge;8 percent. Thus, all patients with stage IB disease should undergo radical local excision with inguinofemoral LND [",
"      <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/56\">",
"       56",
"      </a>",
"      ]. The choice of unilateral or bilateral LND depends upon the location of the lesion (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Inguinofemoral lymphadenectomy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Stage II",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with stage II disease, the most conservative excision technique is used that results in a &ge;1 cm tumor-free margin. Depending upon the size and location of the lesion, this may necessitate radical local excision, partial radical vulvectomy, or the three-incision technique [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/19,56-58\">",
"     19,56-58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Surgical alternatives to radical vulvectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Primary RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary radiation therapy (RT) is generally avoided for management of early stage vulvar cancers because of associated morbidity.",
"   </p>",
"   <p>",
"    In stage I or II disease, surgery rather than radiation therapy (RT) is the preferred mode of therapy for management of the groin nodes unless the patient is not fit enough to tolerate surgery. Primary groin irradiation was compared to primary groin dissection in a Cochrane review. Despite only three studies meeting inclusion criteria, it was concluded that, although primary groin irradiation is associated with less morbidity, it resulted in more groin recurrences than surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/57\">",
"     57",
"    </a>",
"    ]. The radiation dose utilized in at least one study has been criticized; others argue, based upon uncontrolled data, that groin control rates are satisfactory when adequate dose and technique are used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/31,59\">",
"     31,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Positive margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence for benefit with RT in patients with positive or close (&lt;8 mm) margins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/4,24,39\">",
"     4,24,39",
"    </a>",
"    ]. However, re-excision should be considered for positive or very close margins to avoid the toxicity associated with RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Adjuvant RT for node negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been few studies addressing the role of adjuvant RT to reduce local or groin recurrence. The Gynecologic Oncology Group (GOG) has completed a prospective trial to evaluate the role of adjuvant RT in patients with high-risk primary tumors (&ge;4.1 cm in diameter, positive margins, or lymphovascular space invasion) with negative groin nodes (GOG 145). While we await these results, it appears reasonable to consider adjuvant RT to patients with high-risk primary tumors and negative nodes.",
"   </p>",
"   <p>",
"    Management of occult node metastases found at groin dissection will be discussed below under stage III disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Advanced disease: stage III and IV'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Advanced disease: stage III and IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for women with stage III and IV disease is individualized depending upon the size and location of the lesion and the lymph node status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Primary surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with T1 to 2 tumors are generally treated with conservative primary resection, similar to early stage disease (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Stage I'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Stage II'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Surgical management of extensive T3 to T4 disease (tumor spread to the urethra, anus, bladder, rectum, or pelvic bone) requires standard radical vulvectomy with en bloc bilateral inguinofemoral LND with partial removal of any involved structures or pelvic exenteration; depending on the extent of the resection, colostomy or urethral diversion may be necessary. Lymphadenectomy may not be possible when nodes are fixed to the femoral vessels or other vital structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4936?source=see_link\">",
"     \"Radical vulvectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31689?source=see_link\">",
"     \"Exenteration for gynecologic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We and others suggest postoperative RT to the vulva for patients with high-risk of local recurrence (ie, those with stage IVA disease, positive or close margins, and a large number of groin nodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adjuvant RT for node positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with only one microscopically positive groin node, adjuvant RT is generally not recommended. Ipsilateral groin and pelvic irradiation are recommended when there are two or more microscopically positive groin nodes, one or more macroscopically involved lymph nodes, any evidence of extracapsular spread, or if only a small number of lymph nodes were sampled [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are based upon the results of a GOG randomized trial of adjuvant RT versus pelvic node dissection in 114 patients with positive groin nodes after radical vulvectomy and bilateral groin LND [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/66\">",
"     66",
"    </a>",
"    ]. There was a significant benefit for RT over pelvic node dissection in terms of cancer-specific survival (51 versus 29 percent at six years) as well as in local control. Overall survival was not significantly better after RT (six-year overall survival 51 versus 41 percent, p = 0.18) in the entire population, a finding attributed to the greater number of intercurrent deaths in the RT arm (14 versus 2 with pelvic node dissection). However, a significant overall survival benefit from RT as compared to pelvic node dissection was seen in the subgroup of patients with clinically suspicious or fixed ulcerated groin nodes and two or more positive groin nodes. These benefits were not achieved at the cost of more late chronic lymphedema (16 versus 22 percent) or cutaneous desquamation (19 versus 15 percent). Consequently, pelvic LND is rarely performed.",
"   </p>",
"   <p>",
"    In the above study, no survival advantage was seen for RT in patients with only one positive node. Others have examined the role of adjuvant RT in patients with only one positive node, but due to study limitations and conflicting results, this issue remains under debate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/12,67,68\">",
"     12,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toxicity associated with groin irradiation includes wound breakdown, infection, lymphocyst formation, lymphedema, and long-term risk of femoral fracture or hip replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/24,31\">",
"     24,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chemoradiation for locally advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary chemoradiation has been used to treat women with locally advanced (stage III to IVA) or inoperable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/69-77\">",
"     69-77",
"    </a>",
"    ]. Well performed randomized studies have not been conducted, and comparisons to primary surgery have been difficult due to patients selected for operative versus nonoperative management. A Cochrane systematic review on primary chemoradiation for advanced vulvar cancer included results from three studies, all of which were determined to be at moderate- or high-risk of bias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/78\">",
"     78",
"    </a>",
"    ]. Compared to primary surgery, the use of primary chemoradiation (alone) resulted in no significant difference in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality (hazard ratio [HR] 1.09, 95% CI 0.37-3.17)",
"     </li>",
"     <li>",
"      Risk of severe hematologic toxicity (relative risk [RR] 0.75, 95% CI 0.28-2.00) or severe acute gastrointestinal toxicity (RR 0.33, 95% CI 0.05-2.37)",
"     </li>",
"     <li>",
"      Risk of late toxicities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only one trial was included in the analysis that looked at neoadjuvant chemoradiation (followed by surgery) versus primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/78\">",
"     78",
"    </a>",
"    ]. Compared to primary surgery, there was no significant difference in risk of death at five years (RR 1.39, 95% CI 0.94-2.06) or in treatment related toxicity (RR 1.18, 95% CI 0.94-2.06).",
"   </p>",
"   <p>",
"    Still, impressive clinical and pathologic responses have been reported with chemoradiation. This is illustrated in a Gynecologic Oncology Group (GOG) trial that enrolled 71 women and treated them with a split course of radiation therapy (RT) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 of each course of RT) and 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day as a 24 hour continuous infusion for the first four days of each course of RT) followed by planned surgical resection and bilateral inguinofemoral lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/71\">",
"     71",
"    </a>",
"    ]. Chemoradiation was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High rates of pathologic (70 percent) and clinical (48 percent) complete response. Gross residual tumor was present in 54 percent, while only 3 percent had residual unresectable disease.",
"     </li>",
"     <li>",
"      At a median time of follow-up of 50 months (range 22 to 72 months), 55 percent were alive without evidence of recurrence.",
"     </li>",
"     <li>",
"      Serious (grade 4) vulvo-perineal cutaneous reactions occurred in 28 percent. Two patients each developed sepsis or fistulas, and four deaths were related to treatment.",
"     </li>",
"     <li>",
"      Other common toxicities included moist desquamation (20 patients) and surgical wound complications (12 patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chemoradiation is generally accepted as a feasible alternative to radical surgery in selected patients with locally advanced vulvar cancer. If surgery can be performed, we prefer radical resection rather than chemoradiation. However, we offer chemoradiation to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with anorectal or bladder involvement in an effort to avoid colostomy and urostomy",
"     </li>",
"     <li>",
"      Patients with disease that is fixed to the bone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If residual disease remains following chemoradiation, we suggest surgical resection. For those patients with no gross disease and an apparent complete response to chemoradiation, the need for surgery is unclear. Further investigation aims to improve response rates and tumor control and at the same time minimize toxicity.",
"   </p>",
"   <p>",
"    Intensity-modulated radiation therapy (IMRT) reduces the dose to normal tissue and conforms radiation to the target, thereby offering the potential for reducing the risk of treatment-related toxicity while maintaining tumor control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of radiation therapy for gynecologic malignancies\", section on 'Intensity-modulated RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Palliative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been little study of palliative chemotherapy for stage IVB metastatic disease or for frail, inoperable patients. For unclear reasons, chemotherapeutic agents that are active in other squamous cell cancers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , MTX,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , have shown few responses in vulvar cancer; the response that do occur have generally been of short duration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/79-84\">",
"     79-84",
"    </a>",
"    ]. Patients are generally treated with the same combination of 5-FU and cisplatin used for concomitant chemoradiotherapy or with other regimens that are active for squamous cell cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/80,85\">",
"     80,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link\">",
"     \"Management of recurrent or metastatic cervical cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Novel agents such as anti-EGFR tyrosine kinase inhibitors, erlotinib, have shown promising results in small series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/86\">",
"     86",
"    </a>",
"    ]. A single case report describes an objective partial response with cetuximab, a therapeutic monoclonal antibody targeting the EGFR, in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of inguinofemoral node metastases is the most important prognostic factor for survival in patients with vulvar cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/49,88\">",
"     49,88",
"    </a>",
"    ]. Reported five-year survival ranges from 70 to 93 percent for patients with negative nodes to 25 to 41 percent for those with positive nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/80\">",
"     80",
"    </a>",
"    ]. Other prognostic factors include stage (which encompasses size and depth of invasion), capillary lymphatic space invasion, and older age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/16,89\">",
"     16,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival rates by disease stage according to the latest FIGO statistics are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76021 \" href=\"UTD.htm?32/28/33227\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that outcomes are improving over time despite less aggressive surgical procedures, possibly attributable to advances in adjuvant therapy and demographic shifts (younger patients and less advanced disease at presentation) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/51,91\">",
"     51,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of relapses of vulvar cancer occur in the first year, but in one series, almost 10 percent of patients in one series had a vulvar recurrence &ge;5 years after diagnosis, demonstrating the need for long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/32,92\">",
"     32,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal surveillance strategy has not been established and clinical practice is variable. Guidelines are available from the expert group the Society of Gynecologic Oncologists (SGO) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of symptoms and physical examination of the vulva, skin bridge, and inguinal nodes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For low-risk disease (early stage, treated with surgery alone, no adjuvant therapy) &ndash; for the first two years, every six months; and then annually.",
"     </li>",
"     <li>",
"      For high-risk disease (advanced stage, treated with primary",
"      <span class=\"nowrap\">",
"       chemotherapy/radiation",
"      </span>",
"      therapy or surgery plus adjuvant therapy) &ndash; for the first two years, every three months; for year 3 through 5, every six months, and then annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cytology (or vaginal cytology if the cervix has been removed) annually. However, the panel concluded that there was insufficient evidence for use of cytology for detection of cancer recurrence but it may have value in the detection of other lower genital tract neoplasia.",
"     </li>",
"     <li>",
"      Routine use of imaging studies was not recommended. Computed tomography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positron emission tomography should be performed",
"      <strong>",
"       ONLY",
"      </strong>",
"      if recurrence is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vulvar colposcopy and biopsy are indicated if abnormalities are noted on physical examination.",
"   </p>",
"   <p>",
"    Sexual dysfunction and alterations in body image are common after treatment and should be addressed during follow-up visits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT FOR RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for patients with recurrent vulvar cancer take into account patient performance status, prior treatment modalities received, and sites of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vulvar cancer recurrences are classified as local, inguinal, or distant. The distribution of recurrences can be illustrated by data from a series of 502 patients, 187 (37 percent) of whom recurred following primary (surgical) management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perineal &mdash; 53 percent",
"     </li>",
"     <li>",
"      Inguinal &mdash; 19 percent",
"     </li>",
"     <li>",
"      Pelvic &mdash; 6 percent",
"     </li>",
"     <li>",
"      Distant &mdash; 8 percent",
"     </li>",
"     <li>",
"      Multiple &mdash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local perineal recurrences can often be treated successfully by re-excision whereas inguinal recurrences have been associated with a much worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/67,88\">",
"     67,88",
"    </a>",
"    ]. For example, in one series the five-year survival rates according to site of recurrence were [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perineal &mdash; 60 percent",
"     </li>",
"     <li>",
"      Inguinal and pelvic &mdash; 27 percent",
"     </li>",
"     <li>",
"      Distant &mdash; 15 percent",
"     </li>",
"     <li>",
"      Multiple &mdash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RT may be added to surgery or chemotherapy, or used as a sole modality in patients with recurrent vulvar cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/68,97\">",
"     68,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salvage chemotherapy can be considered for patients with distant metastases. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Palliative chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT OF OTHER HISTOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations, epidemiology and pathology of individual histologies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of vulvar melanoma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Basal cell",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal cell carcinomas are locally aggressive but rarely metastasize. Therefore, radical local excision without LND is adequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide local excision is the standard approach to treatment of most vulvar sarcomas. Lymphatic metastases are uncommon.",
"   </p>",
"   <p>",
"    Angiomyxoma is a locally infiltrative lesion treated with wide local excision. The aggressive infiltrative nature and frequent recurrences often require multiple re-excisions with wide margins or radical surgery. Expression of estrogen and progesterone receptors and response to gonadotropin-releasing hormone has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rhabdomyosarcomas, which typically occur in children, are treated with primary chemotherapy followed by surgery as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=see_link&amp;anchor=H4#H4\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Paget disease of the vulva",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vulva is one of the most common sites for extramammary Paget disease. Treatment consists of wide local excision or vulvectomy, depending upon the extent of disease. Radical excision in not required, but a 2 cm margin is preferred. Greater depth of invasion and lymphovascular involvement are poor prognostic markers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/100\">",
"     100",
"    </a>",
"    ]. Some have suggested that inguinal lymphadenectomy be performed in cases with invasive disease or an underlying adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twelve to 58 percent of women experience a local recurrence, which may occur despite negative surgical margins, presumably because of multicentricity and microscopic extension of disease beyond the clinically visible margins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. It may require a margin of 5 cm of normal appearing skin from the visible tumor margin to obtain microscopically clear margins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/104\">",
"     104",
"    </a>",
"    ]. Treatment with Moh's micrographic surgery (ie, microscopically controlled systematic excision of cancerous tissue) may be associated with a lower recurrence rate, particularly for recurrent tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/100,104-106\">",
"     100,104-106",
"    </a>",
"    ]. A full description of the technique of Moh's micrographic surgery is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data addressing the benefit of adjuvant RT. The roles of definitive RT, cytotoxic chemotherapy, and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    in the treatment of Paget disease of the vulva are also not well defined, but may be an option for some patients who are not suitable surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/100,107-113\">",
"     100,107-113",
"    </a>",
"    ]. Overexpression of HER2 suggests a possible role for trastuzumab therapy, but this remains experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term follow-up is indicated because of the high risk of recurrence and the increased risk of noncontiguous carcinoma. Paget disease is associated with underlying invasive adenocarcinomas 4 to 17 percent of the time and another 20 to 30 percent of patients will have or will develop an adenocarcinoma at another nonvulvar location [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/102,116\">",
"     102,116",
"    </a>",
"    ]. The vulva should be inspected annually with a low threshold for biopsy. Screening and surveillance for tumors at other sites (breast, lung, colorectum, gastric, pancreas, and ovary) should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Bartholin gland adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach to therapy is radical vulvectomy with bilateral groin and pelvic LND. Less radical excisions, such as radical local excision or partial vulvectomy with ipsilateral inguinal LND, also appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The lesions are typically deep within the vulva so extensive deep dissection is generally required.",
"   </p>",
"   <p>",
"    Surgical margins are frequently microscopically positive and require postoperative RT to reduce the incidence of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/117\">",
"     117",
"    </a>",
"    ]. If ipsilateral groin nodes are involved, pelvic and bilateral groin radiation may decrease the frequency of regional recurrence.",
"   </p>",
"   <p>",
"    Primary chemoradiotherapy or brachytherapy are therapeutic options that may allow sparing of rectal function or obviate the need for surgery entirely in women with primary carcinoma of the Bartholin gland [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. For advanced disease, single case reports describe activity for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/109\">",
"     109",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Verrucous carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical local excision is usually adequate, as verrucous carcinoma in locally invasive but rarely metastasizes. Suspicious lymph nodes should be biopsied; if positive, then inguinofemoral LND is indicated. RT is contraindicated because it can induce anaplastic transformation and increase the likelihood of metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/14/20714/abstract/124\">",
"     124",
"    </a>",
"    ]. Recurrences are treated surgically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar cancer is a rare disease, though its incidence is increasing, particularly among young women. The majority, about 90 percent, of vulvar cancers are of squamous cell histology. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Vulvar cancer staging",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vulvar cancer is staged using surgical-pathologic staging system based upon findings from the biopsy of the vulvar lesion(s) and the inguinofemoral lymph nodes (also referred to as deep and superficial inguinal or groin nodes) (",
"      <a class=\"graphic graphic_table graphicRef50726 \" href=\"UTD.htm?11/28/11726\">",
"       table 1",
"      </a>",
"      ). Clinical staging is inadequate, as clinical assessment of groin nodes (the most important prognostic factor) is not accurate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staging and primary surgical treatment are typically performed as a single procedure consisting of radical resection of the tumor and inguinofemoral lymphadenectomy (LND). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Inguinofemoral lymphadenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with stage IA disease with no clinically palpable groin nodes do not require inguinofemoral LND. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Stage I'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with stage IB disease that is unilateral and is not located in the anterior portion of the labia minora may undergo unilateral rather than bilateral inguinofemoral LND. All other patients require bilateral LND. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Unilateral versus bilateral lymphadenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sentinel lymph node biopsy (SLNB) appears to be a promising approach, but remains investigational. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sentinel node biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment of squamous cell cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional radical vulvectomy with en bloc inguinofemoral LND results in significant morbidity. In general, primary surgical treatment for women with all stages of vulvar cancer is the most conservative technique that results in a &ge;1 cm tumor-free margin. Depending upon the size and location of the lesion, this may necessitate radical local excision, or partial radical vulvectomy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgical alternatives to radical vulvectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It appears that a tumor-free margin &ge;1 cm minimizes the risk of local recurrence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgical alternatives to radical vulvectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with stage I or II disease with margins &lt;1 cm after excision, we suggest re-excision rather than radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Positive margins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest postoperative RT to the vulva for advanced stage, surgically resected patients with high-risk of local recurrence: those with stage IVa disease and a large number of groin nodes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Primary surgical resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adjuvant pelvic RT including the groin for patients with two or more positive inguinal lymph nodes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adjuvant RT for node positive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest chemoradiation rather than vulvectomy for patients who would require an ostomy as a result of bowel or bladder resection and for patients with disease that is fixed to the bone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Local resection is indicated for residual disease but the necessity of surgery in women who achieve a complete clinical response to chemoradiotherapy is uncertain. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Chemoradiation for locally advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemotherapy, radiation therapy, and surgery are options for management of regional recurrences and metastatic disease. Local perineal recurrences can be treated successfully by reexcision. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Palliative chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment for recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After primary treatment, we follow patients at least twice yearly for five years with a gynecologic examination (visual inspection and palpation of the vulva, skin bridge, and inguinal nodes). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment of other histologies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of nonsquamous cell vulvar malignancies depends upon the histologic type, but in general, surgery is the primary therapy. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment of other histologies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     Vulva. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/3\">",
"      Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/4\">",
"      Gonzalez Bosquet J, Kinney WK, Russell AH, et al. Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2003; 57:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/5\">",
"      Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992; 79:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/6\">",
"      Gonzalez Bosquet J, Magrina JF, Magtibay PM, et al. Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. Gynecol Oncol 2007; 105:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/7\">",
"      Dhar KK, Woolas RP. Lymphatic mapping and sentinel node biopsy in early vulvar cancer. BJOG 2005; 112:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/8\">",
"      Selman TJ, Luesley DM, Acheson N, et al. A systematic review of the accuracy of diagnostic tests for inguinal lymph node status in vulvar cancer. Gynecol Oncol 2005; 99:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/9\">",
"      Stehman FB, Look KY. Carcinoma of the vulva. Obstet Gynecol 2006; 107:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/10\">",
"      Podratz KC, Symmonds RE, Taylor WF, Williams TJ. Carcinoma of the vulva: analysis of treatment and survival. Obstet Gynecol 1983; 61:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/11\">",
"      Andersen BL, Hacker NF. Psychosexual adjustment after vulvar surgery. Obstet Gynecol 1983; 62:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/12\">",
"      Barton DP. The prevention and management of treatment related morbidity in vulval cancer. Best Pract Res Clin Obstet Gynaecol 2003; 17:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/13\">",
"      Tyring SK. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 2003; 189:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/14\">",
"      DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. Am J Obstet Gynecol 1979; 133:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/15\">",
"      Rouzier R, Haddad B, Atallah D, et al. Surgery for vulvar cancer. Clin Obstet Gynecol 2005; 48:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/16\">",
"      De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma. The price of less radical surgery. Cancer 2002; 95:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/17\">",
"      Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990; 38:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/18\">",
"      Rouzier R, Haddad B, Plantier F, et al. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 2002; 100:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/19\">",
"      Farias-Eisner R, Cirisano FD, Grouse D, et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol 1994; 53:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/20\">",
"      Chan JK, Sugiyama V, Pham H, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 2007; 104:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/21\">",
"      Hacker NF, Van der Velden J. Conservative management of early vulvar cancer. Cancer 1993; 71:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/22\">",
"      Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000; :CD002036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/23\">",
"      Helm CW, Hatch K, Austin JM, et al. A matched comparison of single and triple incision techniques for the surgical treatment of carcinoma of the vulva. Gynecol Oncol 1992; 46:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/24\">",
"      Rouzier R, Haddad B, Dubernard G, et al. Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival. J Am Coll Surg 2003; 196:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/25\">",
"      Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003; 13:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/26\">",
"      Hyde SE, Valmadre S, Hacker NF, et al. Squamous cell carcinoma of the vulva with bulky positive groin nodes-nodal debulking versus full groin dissection prior to radiation therapy. Int J Gynecol Cancer 2007; 17:154.",
"     </a>",
"    </li>",
"    <li>",
"     Hacker NF. Vulvar cancer. In: Practical Gynecologic Oncology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.543.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/28\">",
"      Iversen T, Aas M. Lymph drainage from the vulva. Gynecol Oncol 1983; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/29\">",
"      Homesley HD, Bundy BN, Sedlis A, et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). Gynecol Oncol 1993; 49:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/30\">",
"      Courtney-Brooks M, Sukumvanich P, Beriwal S, et al. Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease? Gynecol Oncol 2010; 117:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/31\">",
"      Katz A, Eifel PJ, Jhingran A, Levenback CF. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2003; 57:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/32\">",
"      Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol 2005; 97:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/33\">",
"      Robison K, Steinhoff MM, Granai CO, et al. Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes. Gynecol Oncol 2006; 101:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/34\">",
"      Mocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 2007; 25:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/35\">",
"      Louis-Sylvestre C, Evangelista E, Leonard F, et al. Sentinel node localization should be interpreted with caution in midline vulvar cancer. Gynecol Oncol 2005; 97:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/36\">",
"      Hauspy J, Beiner M, Harley I, et al. Sentinel lymph node in vulvar cancer. Cancer 2007; 110:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/37\">",
"      de Hullu JA, Hollema H, Piers DA, et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol 2000; 18:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/38\">",
"      Ansink AC, Sie-Go DM, van der Velden J, et al. Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a patent blue V injection: a multicenter study. Cancer 1999; 86:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/39\">",
"      Levenback C, Coleman RL, Burke TW, et al. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 2001; 83:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/40\">",
"      Puig-Tintor&eacute; LM, Ordi J, Vidal-Sicart S, et al. Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. Gynecol Oncol 2003; 88:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/41\">",
"      Moore RG, DePasquale SE, Steinhoff MM, et al. Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva. Gynecol Oncol 2003; 89:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/42\">",
"      De Cicco C, Sideri M, Bartolomei M, et al. Sentinel node biopsy in early vulvar cancer. Br J Cancer 2000; 82:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/43\">",
"      Moore RG, Granai CO, Gajewski W, et al. Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecol Oncol 2003; 91:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/44\">",
"      Auger M, Colgan TJ. Detection of metastatic vulvar and cervical squamous carcinoma in regional lymph nodes by use of a polyclonal keratin antibody. Int J Gynecol Pathol 1990; 9:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/45\">",
"      Hakam A, Nasir A, Raghuwanshi R, et al. Value of multilevel sectioning for improved detection of micrometastases in sentinel lymph nodes in invasive squamous cell carcinoma of the vulva. Anticancer Res 2004; 24:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/46\">",
"      Knopp S, Holm R, Trop&eacute; C, Nesland JM. Occult lymph node metastases in early stage vulvar carcinoma patients. Gynecol Oncol 2005; 99:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/47\">",
"      Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/48\">",
"      Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008; 26:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/49\">",
"      Burger MP, Hollema H, Emanuels AG, et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol 1995; 57:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/50\">",
"      Hacker NF, Leuchter RS, Berek JS, et al. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Obstet Gynecol 1981; 58:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/51\">",
"      Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991; 164:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/52\">",
"      Kirby TO, Rocconi RP, Numnum TM, et al. Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol 2005; 98:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/53\">",
"      Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol 2012; 30:3786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/54\">",
"      Magrina JF, Gonzalez-Bosquet J, Weaver AL, et al. Squamous cell carcinoma of the vulva stage IA: long-term results. Gynecol Oncol 2000; 76:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/55\">",
"      G&oacute;mez Rueda N, Vighi S, Garcia A, et al. Histologic predictive factors. Therapeutic impact in vulvar cancer. J Reprod Med 1994; 39:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/56\">",
"      Hacker NF, Berek JS, Lagasse LD, et al. Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 1984; 63:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/57\">",
"      van Der Velden J, Ansink A. Primary groin irradiation vs primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev 2000; :CD002224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/58\">",
"      Morgan MA, Mikuta JJ. Surgical management of vulvar cancer. Semin Surg Oncol 1999; 17:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/59\">",
"      Petereit DG, Mehta MP, Buchler DA, Kinsella TJ. Inguinofemoral radiation of N0,N1 vulvar cancer may be equivalent to lymphadenectomy if proper radiation technique is used. Int J Radiat Oncol Biol Phys 1993; 27:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/60\">",
"      Fonseca-Moutinho JA, Coelho MC, Silva DP. Vulvar squamous cell carcinoma. Prognostic factors for local recurrence after primary en bloc radical vulvectomy and bilateral groin dissection. J Reprod Med 2000; 45:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/61\">",
"      Dusenbery KE, Carlson JW, LaPorte RM, et al. Radical vulvectomy with postoperative irradiation for vulvar cancer: therapeutic implications of a central block. Int J Radiat Oncol Biol Phys 1994; 29:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/62\">",
"      Parthasarathy A, Cheung MK, Osann K, et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol 2006; 103:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/63\">",
"      de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 2006; 60:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/64\">",
"      Le T, Elsugi R, Hopkins L, et al. The definition of optimal inguinal femoral nodal dissection in the management of vulva squamous cell carcinoma. Ann Surg Oncol 2007; 14:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/65\">",
"      Fons G, Groenen SM, Oonk MH, et al. Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol Oncol 2009; 114:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/66\">",
"      Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009; 114:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/67\">",
"      Stehman FB, Bundy BN, Ball H, Clarke-Pearson DL. Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1996; 174:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/68\">",
"      Hruby G, MacLeod C, Firth I. Radiation treatment in recurrent squamous cell cancer of the vulva. Int J Radiat Oncol Biol Phys 2000; 46:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/69\">",
"      Landrum LM, Skaggs V, Gould N, et al. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. Gynecol Oncol 2008; 108:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/70\">",
"      Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/71\">",
"      Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2000; 48:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/72\">",
"      Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 1996; 61:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/73\">",
"      Mulayim N, Foster Silver D, Schwartz PE, Higgins S. Chemoradiation with 5-fluorouracil and mitomycin C in the treatment of vulvar squamous cell carcinoma. Gynecol Oncol 2004; 93:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/74\">",
"      Cunningham MJ, Goyer RP, Gibbons SK, et al. Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 1997; 66:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/75\">",
"      Eifel PJ, Morris M, Burke TW, et al. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995; 59:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/76\">",
"      Wahlen SA, Slater JD, Wagner RJ, et al. Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. Cancer 1995; 75:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/77\">",
"      Gerszten K, Selvaraj RN, Kelley J, Faul C. Preoperative chemoradiation for locally advanced carcinoma of the vulva. Gynecol Oncol 2005; 99:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/78\">",
"      Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev 2011; :CD003752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/79\">",
"      Deppe G, Cohen CJ, Bruckner HW. Chemotherapy of squamous cell carcinoma of the vulva: a review. Gynecol Oncol 1979; 7:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/80\">",
"      Gadducci A, Cionini L, Romanini A, et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 2006; 60:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/81\">",
"      Witteveen PO, van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol 2009; 20:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/82\">",
"      Trop&eacute; C, Johnsson JE, Larsson G, Simonsen E. Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva. Cancer Treat Rep 1980; 64:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/83\">",
"      Muss HB, Bundy BN, Christopherson WA. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study. Am J Clin Oncol 1989; 12:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/84\">",
"      Thigpen JT, Blessing JA, Homesley HD, Lewis GC Jr. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study. Gynecol Oncol 1986; 23:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/85\">",
"      Cormio G, Loizzi V, Gissi F, et al. Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology 2009; 77:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/86\">",
"      Olawaiye A, Lee LM, Krasner C, Horowitz N. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol 2007; 106:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/87\">",
"      Richard SD, Krivak TC, Beriwal S, Zorn KK. Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer 2008; 18:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/88\">",
"      Maggino T, Landoni F, Sartori E, et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 2000; 89:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/89\">",
"      Woolderink JM, de Bock GH, de Hullu JA, et al. Patterns and frequency of recurrences of squamous cell carcinoma of the vulva. Gynecol Oncol 2006; 103:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/90\">",
"      Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/91\">",
"      Landrum LM, Lanneau GS, Skaggs VJ, et al. Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. Gynecol Oncol 2007; 106:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/92\">",
"      Beller U, Sideri M, Maisonneuve P, et al. Carcinoma of the vulva. J Epidemiol Biostat 2001; 6:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/93\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/94\">",
"      Andreasson B, Moth I, Jensen SB, Bock JE. Sexual function and somatopsychic reactions in vulvectomy-operated women and their partners. Acta Obstet Gynecol Scand 1986; 65:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/95\">",
"      Green MS, Naumann RW, Elliot M, et al. Sexual dysfunction following vulvectomy. Gynecol Oncol 2000; 77:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/96\">",
"      Salom EM, Penalver M. Recurrent vulvar cancer. Curr Treat Options Oncol 2002; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/97\">",
"      Wagenaar HC, Colombo N, Vergote I, et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol 2001; 81:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/98\">",
"      Fine BA, Munoz AK, Litz CE, Gershenson DM. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol 2001; 81:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/99\">",
"      Martelli H, Oberlin O, Rey A, et al. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology. J Clin Oncol 1999; 17:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/100\">",
"      Shepherd V, Davidson EJ, Davies-Humphreys J. Extramammary Paget's disease. BJOG 2005; 112:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/101\">",
"      Niikura H, Yoshida H, Ito K, et al. Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution. Int J Gynecol Cancer 2006; 16:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/102\">",
"      Fanning J, Lambert HC, Hale TM, et al. Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. Am J Obstet Gynecol 1999; 180:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/103\">",
"      Tebes S, Cardosi R, Hoffman M. Paget's disease of the vulva. Am J Obstet Gynecol 2002; 187:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/104\">",
"      Hendi A, Brodland DG, Zitelli JA. Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol 2004; 51:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/105\">",
"      Zollo JD, Zeitouni NC. The Roswell Park Cancer Institute experience with extramammary Paget's disease. Br J Dermatol 2000; 142:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/106\">",
"      O'Connor WJ, Lim KK, Zalla MJ, et al. Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 2003; 29:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/107\">",
"      Yokoyama Y, Mabuchi M, Kawabata I, et al. Metastatic vulvar Paget's disease responding to combination chemotherapy: case report. Jpn J Clin Oncol 1990; 20:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/108\">",
"      Yamamoto R, Sakuragi N, Shirato H, et al. Radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease. Gynecol Oncol 2001; 80:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/109\">",
"      Huang GS, Juretzka M, Ciaravino G, et al. Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecol Oncol 2002; 87:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/110\">",
"      Hatch KD, Davis JR. Complete resolution of Paget disease of the vulva with imiquimod cream. J Low Genit Tract Dis 2008; 12:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/111\">",
"      Son SH, Lee JS, Kim YS, et al. The role of radiation therapy for the extramammary paget's disease of the vulva ; experience of 3 cases. Cancer Res Treat 2005; 37:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/112\">",
"      Sendagorta E, Herranz P, Feito M, et al. Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule. J Eur Acad Dermatol Venereol 2010; 24:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/113\">",
"      Hata M, Omura M, Koike I, et al. Role of radiotherapy as curative treatment of extramammary Paget's disease. Int J Radiat Oncol Biol Phys 2011; 80:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/114\">",
"      Brummer O, Stegner HE, B&ouml;hmer G, et al. HER-2/neu expression in Paget disease of the vulva and the female breast. Gynecol Oncol 2004; 95:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/115\">",
"      Richter CE, Hui P, Buza N, et al. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. J Clin Pathol 2010; 63:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/116\">",
"      Parker LP, Parker JR, Bodurka-Bevers D, et al. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 2000; 77:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/117\">",
"      Copeland LJ, Sneige N, Gershenson DM, et al. Bartholin gland carcinoma. Obstet Gynecol 1986; 67:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/118\">",
"      Balat O, Edwards CL, Delclos L. Advanced primary carcinoma of the Bartholin gland: report of 18 patients. Eur J Gynaecol Oncol 2001; 22:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/119\">",
"      Massad LS, De Geest K. Multimodality therapy for carcinoma of the Bartholin gland. Gynecol Oncol 1999; 75:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/120\">",
"      Yamada T, Yanagawa S, Iwai H, et al. High-dose-rate interstitial brachytherapy of Bartholin's gland: A case report. Gynecol Oncol 2000; 77:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/121\">",
"      L&oacute;pez-Varela E, Oliva E, McIntyre JF, Fuller AF Jr. Primary treatment of Bartholin's gland carcinoma with radiation and chemoradiation: a report on ten consecutive cases. Int J Gynecol Cancer 2007; 17:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/122\">",
"      Downs LS, Ghosh K, Dusenbery KE, Cosin JA. Stage IV carcinoma of the Bartholin gland managed with primary chemoradiation. Gynecol Oncol 2002; 87:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/123\">",
"      Tanaka H, Umekawa T, Nagao K, et al. Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel. Int J Gynecol Cancer 2005; 15:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/14/20714/abstract/124\">",
"      Demian SD, Bushkin FL, Echevarria RA. Perineural invasion and anaplastic transformation of verrucous carcinoma. Cancer 1973; 32:395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3248 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20714=[""].join("\n");
var outline_f20_14_20714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical alternatives to radical vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Radical local excision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Three-incision technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Coexistent precancerous lesions or dermatoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inguinofemoral lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Unilateral versus bilateral lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Superficial versus deep lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sentinel node biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF SQUAMOUS CELL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Early stage disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stage I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Stage II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Primary RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Positive margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Adjuvant RT for node negative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Advanced disease: stage III and IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Primary surgical resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adjuvant RT for node positive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chemoradiation for locally advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Palliative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT FOR RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT OF OTHER HISTOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Basal cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Paget disease of the vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Bartholin gland adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Verrucous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Vulvar cancer staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment of squamous cell cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment of other histologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3248|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/57/24465\" title=\"figure 1\">",
"      Incisions radical vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/5/28754\" title=\"figure 2\">",
"      Superfic inguinal lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/23/37233\" title=\"figure 3\">",
"      Deep femoral lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/28/11726\" title=\"table 1\">",
"      Staging vulvar cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/28/33227\" title=\"table 2\">",
"      Vulvar cancer survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31689?source=related_link\">",
"      Exenteration for gynecologic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24201?source=related_link\">",
"      Preoperative management of patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4936?source=related_link\">",
"      Radical vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_14_20715="Lichenoid drug eruption histology differential";
var content_f20_14_20715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic features in lichenoid drug eruption and lichen planus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Differential criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lichen planus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lichenoid drug eruption",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Cornified layer",
"       </td>",
"       <td>",
"        Compact hyperorthokeratosis, seldom a moderate degree of parakeratosis",
"       </td>",
"       <td>",
"        Focal parakeratosis; cytoid bodies in the cornified layer",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Epidermis",
"       </td>",
"       <td>",
"        Thickened stratum granulosum at acrosyringia and acrotrichia, irregular saw-tooth-like acanthosis, necrotic keratinocytes in the lower epidermal layers",
"       </td>",
"       <td>",
"        Thickened stratum granulosum possible, however, with focal interruption of the granular layer, cytoid bodies in the granular layer, necrotic keratinocytes scattered in all epidermal layers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermis",
"       </td>",
"       <td>",
"        Mostly a superficial dermal inflammatory infiltrate; seldom eosinophils",
"       </td>",
"       <td>",
"        More often a deep dermal inflammatory infiltrate (especially in non-photodistributed lichenoid drug eruption); admixture of eosinophils and plasma cells possible*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Presence of plasma cell is a regular finding in biopsies from mucous membranes independently of the origin of dermatosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20715=[""].join("\n");
var outline_f20_14_20715=null;
var title_f20_14_20716="Air embolism clinical findings";
var content_f20_14_20716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings in air embolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physical findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Dyspnea (100 percent incidence)",
"        </p>",
"        <p>",
"         \"Gasp reflex\"*",
"        </p>",
"        <p>",
"         \"Sucking sound\"&bull;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Tachypnea",
"        </p>",
"        <p>",
"         Wheeze",
"        </p>",
"        <p>",
"         Rales",
"        </p>",
"        <p>",
"         Respiratory failure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Substernal chest pain",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hypotension",
"        </p>",
"        <p>",
"         Tachycardia",
"        </p>",
"        <p>",
"         Mill wheel murmur&Delta;",
"        </p>",
"        <p>",
"         Signs of right heart failure (eg, elevated JVD)",
"        </p>",
"        <p>",
"         Shock",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Sense of doom",
"        </p>",
"        <p>",
"         Dizziness/lightheadedness",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Change in mental status",
"        </p>",
"        <p>",
"         Focal neurological deficits",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Crepitus over superficial vessels (seen rarely in setting of massive air embolus)",
"        </p>",
"        <p>",
"         Livedo reticularis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Ocular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Bubbles within the retinal arteries",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A gasp or cough is at times reported when a bolus of air enters the pulmonary circulation.",
"     <br>",
"      &bull; A sucking noise can be heard on occasion when air is sucked into the intravascular space, such as when air embolism occurs as a complication of a central line.",
"      <br>",
"       &Delta; The mill wheel murmur is a relatively specific sign classically associated with venous air embolism but only rarely heard. It is a churning sound heard throughout the entire cardiac cycle and is caused by the movement of air bubbles in the right ventricle.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20716=[""].join("\n");
var outline_f20_14_20716=null;
var title_f20_14_20717="Chronic respiratory alkalosis";
var content_f20_14_20717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Compensatory response to chronic respiratory alkalosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 244px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Combined significance bands for plasma pH and concentrations of H+ and HCO3- in chronic respiratory alkalosis in humans. In uncomplicated chronic respiratory alkalosis, values for the H+ and HCO3- concentrations will, with an estimated 95 percent probability, fall within the band. Values lying outside the band indicate the presence of a complicating metabolic acid-base disturbance. Note that the compensatory reduction in the plasma HCO3- concentration is so effective that there is little fall in pH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Gennari, JF, Goldstein, MB, Schwartz, WB, J Clin Invest 1972; 51:1722, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20717=[""].join("\n");
var outline_f20_14_20717=null;
var title_f20_14_20718="Lyme sxs frequency";
var content_f20_14_20718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Percentage of symptoms reported among Lyme disease patients,* by year - United States, 1992-2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * N = 150,829.",
"    </div>",
"    <div class=\"reference\">",
"     Bacon, RM, Kugeler, KJ, Mead, PS. Surveillance for Lyme disease--United States, 1992-2006. MMWR Surveill Summ 2008; 57:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20718=[""].join("\n");
var outline_f20_14_20718=null;
var title_f20_14_20719="Transverse femur fracture";
var content_f20_14_20719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse femoral shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Klane White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_14_20719=[""].join("\n");
var outline_f20_14_20719=null;
